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Abstract  
 
Outcomes of hepatitis C virus (HCV) infection and treatment depend on viral and 
host genetic factors. We use human genome-wide genotyping arrays and new 
whole-genome HCV viral sequencing technologies to perform a systematic genome-
to-genome study of 542 individuals chronically infected with HCV, predominately 
genotype 3. We show that both HLA alleles and interferon lambda innate immune 
system genes drive viral genome polymorphism, and that IFNL4 genotypes 
determine HCV viral load through a mechanism that is dependent on a specific 
polymorphism in the HCV polyprotein. We highlight the interplay between innate 
immune responses and the viral genome in HCV control.  
Introduction 
 
Hepatitis C virus (HCV) infection presents a major health burden, infecting more than 
185 million people worldwide1 and leading to liver failure and hepatocellular cancer. 
Both host and virus genetic variations are associated with important clinical 
outcomes. Host genetic polymorphisms, most notably in the interferon lambda 3 and 
4 locus, are associated with spontaneous clearance of the virus, response to 
treatment, viral load and progression of liver disease2–6. Similarly, viral genotypes, 
and distinct viral genetic motifs have been associated with the response to interferon 
based therapies7,8 whilst resistance-associated substitutions (RASs) have been 
identified for most of the new oral direct-acting antiviral (DAA) drugs9–12. HCV can be 
divided into seven major genotypes, and most of the genetic data acquired to date 
focuses on HCV genotype 1 with a paucity of data addressing other genotypes. HCV 
genotype 3 is of particular interest as this genotype is known to infect 53 million 
people globally13, has particularly high prevalence in the UK, and is associated with a 
higher failure rate to DAA therapies14,15. Despite these key observations, there has 
been few previous attempts to generate large full-length HCV genome datasets and 
to broadly assess the impact of host genes on the HCV viral genome.  
 
Previous work has shown that within-host virus diversity evolves in response to the 
adaptive immune system, including candidate genes studies of the association 
between the human leukocyte antigen (HLA) type I proteins with the HCV 
genome16,17. HLA molecules are expressed on most cell types and present viral 
peptides (epitopes) to cytotoxic T lymphocytes (CTLs) that kill infected cells. CTL-
mediated killing of virus-infected cells drives the selection of viral polymorphisms 
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(“escape” mutants) that abrogate T cell recognition18. Understanding how host HLA 
molecules impact on viral selection has important implications for the development of 
HCV T cell vaccines that aim to prevent infection19,20.  Since both HLA molecules and 
the viral epitopes they present are highly variable, a comprehensive host genome to 
viral genome analysis at scale is needed to assess the relative contribution of host 
HLA molecules in driving HCV viral genetic change. An analysis of this kind may also 
reveal other host genes that play a key role in shaping the HCV viral genome.  
 
Whole genome viral sequencing for HCV is particularly challenging since HCV is 
genetically highly diverse both within and between infected individuals21,22. To 
overcome this we have recently developed new technologies that use next 
generation sequencing with targeted enrichment23,24 to obtain a consensus genome 
in each individual at scale. The falling cost of host genotyping, in combination with 
large reference panels of human genomes25 and advances in statistical 
methodologies, mean that it is possible to obtain accurate inference of millions of 
host genetic polymorphisms, including classical HLA alleles26–28. For the first time, 
these developments allow an unbiased genome-to-genome analysis29, in large 
cohorts of HCV infected individuals, to better understand how host genetic variation 
drives changes within the virus during persistent infection at a population level.  
 
We generated data from a cohort of 601 HCV infected patients (recruited to a clinical 
study called BOSON30) to systematically look for associations between host and virus 
genomes, exploiting the fact that while host genetics remain fixed, the virus mutates, 
allowing it to evolve during infection. We provide evidence that polymorphisms 
relevant to the innate (IFNL4) and adaptive immune systems (HLA genes) are 
associated with HCV sequence polymorphisms (so-called “footprints” in the viral 
genome). We show that an interaction between host IFNL4 genotype determines 
HCV viral load through a mechanism that is dependent on a specific polymorphism in 
the HCV polyprotein. By assessing rates of viral evolution in individuals with different 
IFNL4 genotypes, we highlight systematic differences in the innate immune response 
and discuss how these might relate to previous associations with spontaneous 
clearance and clinical treatment. We discuss the potential for a joint analysis of host 
and viral genome data to provide information on underlying molecular interactions 
and their importance in treating and preventing HCV, and other viral infections, in the 
era of genomic analysis.  
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Results 
Sample description and genetic structure 
 
DNA samples from 567 patients within the BOSON clinical study30 (out of 601 
patients) were genotyped using the Affymetrix UK Biobank array. This array 
genotypes over 800,000 bi-allelic single nucleotide polymorphisms (SNPs) across 
the human genome, including a set of markers specifically chosen to capture 
common HLA alleles. Pre-treatment plasma samples from 583 patients in the same 
study were analysed to obtain HCV whole genome consensus sequences using a 
high-throughput HCV targeted sequence capture approach coupled with Illumina 
sequencing23.  
 
Both full-length HCV genome sequences and human genome-wide SNP data were 
obtained on a total of 542 patients of mainly White and Asian self-reported ancestry 
infected with HCV genotypes 2 or 3 (see Supplementary Table S1 for patient 
demographics). After quality control and filtering of the human genotype data, 
approximately 330,000 common SNPs with minor allele frequency greater than 5% 
were available for analysis along with inferred alleles at both class I and II HLA 
genes. The full-length HCV genome is approximately 9.5 kb, corresponding to over 
3000 encoded amino acids. In our dataset, 1226 sites of the HCV proteome were 
defined to be variable (where at least 10 isolates have an amino acid which differs 
from the consensus amino acid) to have minimal statistical power for analysis.  
 
We characterised human genetic diversity in the cohort via principal component 
analysis (PCA). The first two principal components (PCs) corresponded to the 
sample’s 83% White and 14% Asian self-reported ethnicity, (Supplementary Figure 
S1), which differed significantly in some of the inferred HLA alleles frequencies 
(Supplementary Table S2) consistent with previous observations31. The third PC 
separates individuals with Black self-reported ethnicity from the rest of the cohort.  
We summarised virus diversity by constructing a maximum-likelihood tree of the 
consensus sequences from each patient (Supplementary Figure S2). Major clades 
in the tree separated HCV genotypes 2 (8% of the sample) and 3 (which in turn 
comprised clades representing subtype 3a and non-subtype 3a samples (90% and 
2% of the total respectively)). A PCA on virus nucleotides sequence data reflected 
the structure of the tree, specifically at the level of virus subtypes (Supplementary 
	 5	
Figure S3).  We used the PCs as covariates to control for viral population structure 
in the primary genome-to-genome analysis.  
 
Labelling the inferred tree of viral diversity with either genetic ancestry (measured by 
host PCs) or self-reported ethnicity revealed a group within genotype 3 that was 
strongly associated with Asian ancestry (Supplementary Figure S2). The viral group 
associated with hosts of Asian ancestry is basal on the phylogenetic tree relative to 
the viral clade associated with White ancestry. The observed relative reduction in 
viral diversity within hosts of White ancestry is likely to be explained by the 
introduction and spread of HCV genotype 3a from South Asia where it is endemic13.  
Systematic host genome to virus genome analysis 
 
We used the genotyped autosomal SNPs in the host genome to undertake genome-
wide association studies, where the traits of interest were the presence or absence of 
each amino acid at the variable sites of the virus proteome, resulting in nearly one 
billion association tests. The analyses were performed on a compute cluster using 
logistic regression as implemented in PLINK232, adjusting for sex, population 
structure, and assuming an additive model. To control for population structure, we 
included the first three PCs of the host and the first 10 PCs of the virus as covariates. 
We note that failure to control for either covariates leads to a significant inflation in 
the association test statistics (Supplementary Figure S4), as would be expected 
given the observed correlation in population structure of the virus and the host 
(Supplementary Figures S1, S2 and S3). Assuming a human genome-wide 
significance threshold of 5x10-8 33,  and that amino acid variants in the viral genome 
are approximately uncorrelated once the population structure is accounted for, then a 
Bonferroni correction34 results in a significance threshold of approximately 2x10-11.   
 
Figure 1 shows the result of the genome-to-genome association tests and highlights 
the strongest signals of association.  Across the human genome, the most significant 
associations were observed between multiple SNPs in the major histocompatibility 
complex (MHC; chromosome 6) locus and a virus amino acid variant in non-
structural protein 3 (NS3). Three other associations were observed between multiple 
SNPs in the host MHC and virus amino acids in NS3 and NS4B proteins (P<2x10-9). 
Outside the MHC, the strongest association between host and virus was detected 
between the SNP rs12979860 in the IFNL4 gene (chromosome 19) and HCV amino 
acids at position 2570 in NS5B protein (P=1.98x10-9). Observed variability in the 
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density of nominally significant associations (Figure 1) is largely explained by 
variability in host and virus sequences, for example in the hyper-variable region 
(HVR) of HCV in E2 protein. 
 
 
Figure 1. Human to hepatitis C virus genome-wide association study in 542 patients. 
The lower arc shows the human autosomes from chromosome 1 to 22, and the 
upper arc shows the HCV proteome from core (C) to NS5B. The red line represents 
the most significant association, P<2x10-11. The four green lines represent 
suggestive associations, P<2x10-9. The thin grey lines represent associations with 
P<10-5. The outer mini-panels represent, on the upper arc, the viral diversity as 
measured by Shannon entropy and, on the lower arc, the density of human SNPs in 
bins of 1Mb, with higher values away from the centre for both upper and lower arcs. 
 
We observed 169 associations between human SNPs mapping to two loci and five 
HCV amino acid sites (P<4x10-9) (Supplementary Table S3). Since these 
associations represent places where host genetic diversity has impacted on virus 
sequence diversity we refer to them as “footprints”. We interpret the signals of 
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association in the MHC region to indicate the effect of the adaptive immune system 
on genetic diversity in the virus genome. Whilst the effect of MHC was anticipated, 
the strong signal of association of the interferon lambda region with viral diversity 
indicates additional effects of the innate immune response. 
HLA alleles to virus genome 
 
SNPs in the MHC which show strong association with viral amino acids are likely to 
be correlated with alleles at HLA genes due to extensive linkage disequilibrium 
across the region35,36.  The HLA repertoire of a patient defines which viral peptides 
will be presented to T cells as part of the adaptive immune response, and can lead to 
the selection of viral mutations away from these peptides (“escape mutations”)16,37–40. 
Upon transmission to another host, with a different HLA repertoire, reversion to the 
wild type may occur (“reversion mutations”).  
 
Using the tree inferred from whole-genome viral sequences we estimated the 
ancestral amino acids at internal nodes of the tree41. Inferring the changes along the 
terminal branches of the tree aims to control for the confounding between host and 
virus population structures42 by looking at viral mutations after infection.  To test for 
association between specific HLA alleles and viral amino acids, we constructed a 2x4 
contingency table for each amino acid present at variable sites, and counted the 
number of changes and non-changes from ancestral amino acids in carriers, and 
non-carriers, for each imputed HLA allele (see Figure 3a for an example). We used a 
Fisher’s exact test to assess significance of the association along the viral genome 
(Figure 2a), and a permutation approach to estimate the false discovery rate (FDR) 
as the P-values for discrete counts with low number of observation was not uniform 
in distribution43,44.  
 
At a 5% FDR, 24 combinations of HLA alleles and HCV sites were significant (Table 
1) and this increased to 153 associations at a 20% FDR (Supplementary Table S4). 
Out of 21 viral amino acid positions showing signals of association with one or more 
HLA alleles, 12 were located in previously reported HCV genotype 3 epitopes20 
(Table 1), which represents a strong enrichment (odds ratio,  OR=5.2, P=2.8x10-4). 
We also observed that the NS3 protein was strongly enriched for association signals 
with HLA alleles (OR=6.6, P=5.68x10-5) and that three HLA alleles were nominally 
enriched for association signals with viral amino acids (HLA-A*31:01, OR=10.5, 
P=0.02; HLA-A*32:01, OR=13, P=0.01; HLA-A*68:02, OR=18.5, P=8x10-4). The 
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strongest HLA footprinting signals are found with common alleles at HLA-A and HLA-
B genes, although signals are also found in HLA-C and the class II gene HLA-DQA1. 
At position 1646 in the HCV genome (in NS3), the footprint is seen with multiple HLA 
alleles (B*08:01, C*07:01 and DQA1*05:01), although this is potentially a result of 
linkage disequilibrium between these HLA alleles (r2 between B*08:01 and C*07:01 = 
0.49, and r2 between B*08:01 and DQA1*05:01 = 0.22; Supplementary Figure S5). 
As the majority of the cohort are patients infected with genotype 3a virus and self-
reporting as White (411 out of 542), we repeated the HLA analysis on specifically 
these patients as an additional check that the associations are not driven by 
correlations between viral genotype and host ancestry. Broadly the association 
evidence was consistent with analysis of the whole cohort with some loss of power 
due to reduced sample size (Supplementary Table S5 and Supplementary 
Figures S6) and potentially differential effects between the viral subtypes.      
 
 
 
Figure 2. Association between HCV amino acids and (a) HLA alleles, (b) IFNL4 
genotypes using Fisher’s exact test, and (c) pre-treatment viral load (log10PTVL) 
using linear regression. Sites in experimentally validated epitopes in HCV genotype 
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320 are indicated by a plus sign. Viral sites 1444, 2414 and 2570 are coloured as red. 
Dashed lines represent a 5% false discovery rate. (d) HCV polyprotein.   
 
The most significant association was found for HLA-A*01:01 and the viral amino acid 
at position 1444 in the NS3 protein. Having identified a viral amino acid subject to 
footprint by a host HLA allele, we can look for evidence of escape and/or reversion 
mutations at this viral site (Figure 3a). The HLA-A*01:01 allele was associated with a 
tyrosine-to-phenylalanine change in the NS3 protein (Y1444F). Carriers of HLA-
A*01:01 allele very rarely lose an existing F amino acid, and there is a strong relative 
increase in the inferred number of changes from Y to F in individuals that carry HLA-
A*01:01 allele (P=1x10-32), consistent with known T cell selection at this epitope45. 
The signal of association is at the ninth amino acid of the experimentally validated 
epitope (Supplementary Figure S7) which is known to be prone to escape 
mutations as it alters the contact between the epitope and the HLA groove which 
presents the antigen46.  
 
 
 
 
 
 
 
Figure 3. Association between viral position 1444 
and HLA-A alleles. (a) Table of changes to and 
from the ancestral amino acids in individuals with 
and without the HLA-A*01:01 allele. (b) Estimated 
effect size (log odds ratio) of common HLA-A 
alleles and the top associated SNP (rs3129073) 
on the possibility of mutation from F to Y at viral 
position 1444. The black dots represent the effect 
size estimate and the bar represent the 95% 
confidence intervals.   
 
 
 
 
 
 
 
 
 
 
To quantify the influence of the host’s HLA at position 1444, we estimated the odds 
ratio separately for the most common HLA-A alleles, and the most associated SNP in 
log(OR)
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A*33:01
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A*33:03
A*11:01
A*29:01
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the region (rs3129073), on the amino acid changes from F to Y. Figure 3b shows 
that our data support a very strong signal for individuals carrying HLA-A*01:01 allele 
to carry a virus with the non-antigenic F amino acid which is consistent with the size 
of effect of the rs3129073. A weaker signal for HLA-A*33:01 allele in the opposite 
direction is likely explained by these alleles acting as surrogates for non-HLA-
A*01:01 allele carriers. Association analysis across the HLA region which was 
conditioned on HLA-A*01:01 allele (Supplementary Figure S8) removed all 
association signals (P>10-4), suggesting that the primary HLA-A*01:01 association 
explains other associations in the region with amino acids at position 1444.  
Using the 27 HLA and viral amino acid associations that surpass the 20% FDR 
threshold, and have sufficient observations to estimate the ORs, we observed a 
negative correlation between the ORs of escape and reversion (R=-0.65, P<0.01; 
Supplementary Figure S9). These observations are consistent with HLA alleles 
driving patterns of both escape and reversion at viral amino acids. Our analysis 
provides a map of their influence across the HCV genome. 
 
IFNL4 variants to virus genome  
 
Variants in the interferon lambda region have been associated with multiple HCV 
outcomes including spontaneous clearance, treatment response, viral load and liver 
disease progression2,3,47. In our genome-wide analysis, variants around the interferon 
lambda region showed the strongest association with HCV amino acids outside the 
MHC region (the top associated SNP is rs12979860, P=1.98x10-9). For that SNP, the 
CC genotype is associated with higher rates of spontaneous clearance and 
interferon-based treatment response, putatively due to the fact that it tags a deletion 
polymorphism (rs368234815) which prevents IFNL4 expression48. In our cohort, only 
two individuals had discordant genotypes for rs12979860 and rs368234815 (which 
was imputed), resulting in a strong linkage disequilibrium (r2= 0.992) between these 
two SNPs. Non-CC genotypes express IFNL4 and have increased expression of 
interferon stimulated genes (ISGs)49.  
 
To interrogate these associations further, we compared viral amino acid changes 
between hosts with CC and non-CC genotypes at the IFNL4 SNP rs12979860 using 
the same Fisher’s exact test as described above. The most significant association 
was with changes to and away from valine (V) at position 2570 in the viral NS5B 
protein (P=1.94x10-11) (Figure 2b). We replicated this association using an 
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equivalent analysis in an independent study of 360 patients of European ancestry 
chronically infected with HCV genotypes 2 or 34 (one-sided P=0.005). In addition, a 
candidate gene association study in a genotype 1b single source infection cohort has 
shown an association between IFNL4 genotypes (rs12979860) and an amino acid  in 
the same region of NS5B (position 2609)38 reinforcing the potential role of the locus 
in interactions with the host immune system. 
 
Overall, using a 5% FDR, 11 significant associations were observed between IFNL4 
genotypes and amino acid positions located in core, E2, NS5A and NS5B proteins 
(Supplementary Table S6). These amino acids are not located in any known HCV 
genotype 3 HLA-associated epitopes, however one of the sites (position 109 in the 
core protein) is also associated with HLA-B*41:02 in our dataset (P=4.3x10-6, Table 
S4). The top signals of associations between IFNL4 genotypes and viral variants are 
located in viral proteins known to be HCV immune response targets38, and those 
which disrupt human proteins in order to escape mechanisms of innate immunity50. 
We used a permutation approach to determine if any of the viral proteins are 
enriched in the number of associations with IFNL4 genotypes. Only the core protein 
is nominally (P<0.05) enriched, while the NS5A protein is nominally depleted in the 
number of associations with the IFNL4 genotypes. 
 
In the 487 genotype 3a infected patients, we defined the population consensus to be 
the most common amino acid and assessed whether regions of the viral genome 
with either high diversity (HVR1, HVR2 and HVR3) or previously reported to be 
correlated with interferon based therapy outcome (the IFN sensitivity-determining 
region (ISDR), protein kinase phosphorylation homology domain (PePHD) and the 
protein kinase binding domain (PKR-BD))7,51,52 showed difference in the number of 
changes from the population consensus, between patients with the CC and non-CC 
genotypes (Supplementary Table S7). Patients with the CC genotype had an 
increased number of mutations away from the population consensus in the ISDR 
(P=3.5x10-4), HVR2 (P=2.5x10-6) and PKR-BD (P=0.012) regions.  However, we 
observed the same pattern across the genome (P=5.06x10-6) suggesting that the 
IFNL4 effect is not necessarily specific to these regions.  
 
To further investigate the selective pressures on the virus in IFNL4 CC and non-CC 
patients, we estimated the rates of synonymous (dS) and non-synonymous 
substitutions (dN) in genotype 3a infected patients (Figure 4). Whilst there was no 
difference in dS in CC and non-CC patients (Figure 4a, P=0.68), dN was significantly 
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higher in CC patients (Figure 4b, P=1.6 x10-8). The lower dN/dS ratio in non-CC 
patients (P=1.3x10-10) is potentially indicative that the virus is under a stronger 
purifying selection (Figure 4c). This hypothesis is supported by the observation that 
for the same rate of synonymous substitutions dS (a surrogate for the time and 
amount of divergence), the HCV genome is under a larger purifying selection in 
patients with IFNL4 non-CC genotype than CC genotype (Figure 4d).  
 
Estimating dN/dS ratio per viral gene showed that this ratio was significantly higher 
(P<0.05) in CC patients compared to non-CC patients in E1, E2, NS3 and NS5B 
(Supplementary Figure S10). A sliding window analysis across the HCV genome 
showed that in the full cohort E1 and E2 genes had a much higher dN/dS ratio 
compared to the rest of the genome. These envelope genes include hyper-variable 
regions (HVRs), and are thought to be the primary targets of the antibody-based 
immune response (Supplementary Figure S11).  
 
We also tested whether IFNL4 genotypes had an impact on HLA presentation as 
measured by our foot printing analysis. We did not find any consistent evidence for 
interaction between individual sites presentation by HLA alleles and IFNL4 
genotypes (Supplementary Figure S12), or in the mean number of escape 
mutations in CC and non-CC patients when comparing HLA allele carriers and non-
HLA allele carriers.  
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Figure 4. Association between IFNL4 genotypes and rates of synonymous (dS) and 
non-synonymous (dN) substitutions in HCV genome in genotype 3a infected patients. 
Each blue dot represents the mean dS, dN or dN/dS ratio per patient. The mean and 
95% confidence intervals are shown as black dots and bars. (a) Rate of synonymous 
substitution (P=0.68). (b) Rate of non-synonymous substitution (P=1.6x10-8). (c) 
dN/dS ratio (P=1.28x10-10). (d) The joint distribution of dS and dN/dS in individuals 
with the IFNL4 non-CC genotype (red dots) and with the CC genotype (blue dots). 
 
Host and virus genetic determinants of viral load 
 
Pre-treatment viral load (PTVL, as measured in IU/ml) was available for all patients 
(See Supplementary Table S1 for details of the cohort). We performed a genome-
wide association study in patients infected with HCV genotype 3a using an additive 
linear regression model adjusted for sex and the three first host PCs for log10 
transformed PTVL (log10PTVL) (Figure 5a). We replicated the known association 
between IFNL4 variants on chromosome 19 and viral load3 (rs12979860, P=5.9x10-
10) with the non-CC genotype conferring an approximately 0.45-fold decrease in viral 
load (mean for non-CC=3.4760x106 IU/mL and for CC=6.3447x106 IU/mL). 
 
We also performed a genome-wide association study to detect associations between 
viral amino acids and viral load (Figure 2c). The only amino acid significantly 
associated with log10PTVL at a 5% FDR was a change from a serine (S) to an 
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asparagine (N) at position 2414 in NS5A protein (P=9.21x10-7) (Figure 5b). This site 
is one of the 11 sites significantly associated (5% FDR) with IFNL4 genotypes 
(Figures 2b and 2c). In patients with a serine at position 2414, the association 
between IFNL4 genotypes and PTVL is highly significant (P=9.37x10-9). However, we 
observed no association between (P=0.9) log10PTVL and IFNL4 genotypes in 
patients infected with a virus that has a different amino acid  (Figures 5c and 5d). In 
other words, the host’s IFNL4 genotypes determine viral load only if they are infected 
by a virus with the serine amino acid at position 2414 in NS5A protein (Figures 5c 
and 5d). The interaction is statistically significant when analysing either the whole 
cohort (P=0.0173) or just patients with genotype 3a infections who self-report as 
being White (P=0.01692). Together the combinations of a non-CC genotype and a 
serine viral amino acid at position 2414 are inferred to result in a 0.57-fold decrease 
in viral load compared to all other combinations (mean viral load for non-CC and 
serine at position 2414 =2.8083x106 IU/mL and all other combinations =6.4735x106 
IU/mL).  
 
 
Figure 5. Association between log10 transformed pre-treatment viral load (log10PTVL) 
and human and virus genetic variants in genotype 3a infected patients. (a) 
Association between human SNPs and log10PTVL. (b) Distribution (blue dots), 
estimated mean and 95% confidence interval (shown as black dots and bars) of 
log10PTVL stratified by amino acids present at viral position 2414 (P=9.21x10-7), (c) 
by IFNL4 (CC, CT and TT) genotypes in patients whose virus carries a serine at 
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position 2414 (P=9.37x10-9) (d) or in patients whose virus does not carry a serine 
amino acid at position 2414 (P=0.9).  
 
To investigate whether the mutations associated with higher viral loads and/or IFNL4 
genotypes influence replication ability, each was introduced into the modified S52 
replicon of genotype 3a53 and replication assessed in short term Huh7.5 cell cultures. 
As a positive control, introduction of an alanine to threonine change at position 1192 
led to a 10-fold increase in in vitro replication, as previously reported54 
(Supplementary Figure S13). Introduction of the change from a serine to an 
asparagine at position 2414 resulted in approximately a 10-fold increase in 
replication (Supplementary Figure S13). However, introducing a range of other 
mutations nominally associated with higher viral load produced more variable 
outcomes. The mutant I1851V replicons show a 10-fold reduced replication 
compared to the wild type S52 replicon while others showed 2-fold to 3-fold increase. 
(Supplementary Figure S13). No mutations associated with IFNL4 genotypes other 
than N2414S led to altered replication phenotypes in vitro. 
 
We assessed the relationship between IFNL4 genotypes, viral amino acids and viral 
load in genotype 3a isolates by estimating the effect of the CC genotype on the 
chances of observing a change from the consensus (to non-consensus) using a 2x2 
Fisher’s exact test (only using data in which the consensus is inferred to be 
ancestral). These odds ratios were compared against the estimated effect of non-
consensus amino acids on viral load (whilst accounting for IFNL4 genotypes) at sites 
associated with the IFNL4 genotypes at a 20% FDR (Supplementary Figure S14). 
We observe a positive relationship (R=0.42, P=0.005) whereby non-consensus 
amino acids which are increased in frequency in individuals with a CC genotype tend 
to also associate with increased viral load. The same positive relationship was 
observed when estimating the effect on viral load in individuals with a CC genotype 
only (R=0.35, P=0.02) or a non-CC genotype only (R=0.4 and P=0.007). A nominally 
significant trend was observed when the analysis was done for all variant positions in 
the viral genome (R=0.099 and P=0.04) (Supplementary Figure S15).  
 
Discussion 
 
Here we report the first systematic analysis of associations between variation in 
human and HCV genomes in a large patient cohort. Advances in DNA and RNA 
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sequencing technology and new bioinformatics tools have allowed full-length viral 
consensus sequences to be obtained in large number of patients for reasonable cost 
(approximately £100 per sample), as well as host genetic data at millions of directly 
assayed and imputed polymorphisms (approximately £75 per sample). We apply a 
fast and simple approach to test for association between host and pathogen variants, 
using a logistic regression analysis corrected for both human and viral population 
structures by using the principal components of the genome-wide data as covariates 
(60 hours for approximately 2500 association studies of 330,000 SNPs). We also 
applied a contingency table analysis based on the inferred viral amino acid changes 
since infection. We anticipate that with the reduction in the cost of sequencing and 
genotyping, and the increasing interest in studying large patient cohorts, analyses of 
this kind will become a powerful approach to understanding infectious diseases.  
 
We found strong evidence for the adaptive immune system exerting selective 
pressures on the HCV genome, presumably by preferentially selecting viral 
mutations that avoid antigenic presentation by the host’s HLA proteins. Some of the 
observed associations are located in experimentally validated viral epitopes20, 
however others have not been described experimentally and most likely represent 
sites of novel T cell escape mutations. Assuming that our analysis removes biases 
associated with population structure and incorrect ancestral inference, 5% of the viral 
amino acids (153/3021) are associated with HLA alleles (at 20% FDR). These data 
highlight the importance of the adaptive immune system in driving viral evolution, and 
serves as a map of the targets of T-cell based immunity along the HCV genome 
which can aid vaccine design and development20.  
 
In addition to the HLA, we now show that IFNL4 activity may significantly shape the 
HCV viral genome. Previous studies have shown the “favourable” CC IFNL4 
genotype increases the chances of spontaneous resolution and interferon-based 
treatment success2–6. Prokunina-Olsson et al. have shown that the “favourable” CC 
IFNL4 genotype abolishes the expression of IFNL446, whereas in individuals with the 
“unfavourable” non-CC IFNL4 genotype, IFNL4 expression is maintained leading to 
the downstream up-regulation of hepatic ISGs expression via the JAK-STAT 
pathway49. The expression of ISGs has been shown to render the host less 
susceptible to exogenous INFα/γ stimulation and is associated with more infected 
cells in the liver56. To date it has been presumed that this fully explains why patients 
with specific IFNL4 genotypes have differential outcomes during primary infection or 
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with drug therapy56,57.  Our analysis adds to this story, with the observation that 
IFNL4 variants also impact significantly on the HCV viral genome at multiple amino 
acid sites. Indeed, these were the strongest footprinting signals in our systematic 
analysis outside HLA region. The most significant association was at position 2570 in 
the viral NS5B protein; an association that we replicated in an independent cohort 
infected with HCV genotype 2 or 3. An association between IFNL4 and amino-acid 
variability in NS5B protein, has previously been reported in a candidate gene study38 
in a single source infection cohort. IFNL4 has also been associated with a viral SNP 
associated with DAA resistance in HCV genotype 1 infection58 although this 
association has not been replicated in our HCV genotype 3 cohort59. However, the 
broader impact of interferon lambda host genes that are associated with, and 
potentially select for, specific viral variants has not been previously recognised. 
 
As far as we are aware, we also report the first association between a single virus 
amino acid variant (serine vs. non-serine at position 2414 in NS5A) and HCV viral 
load. HCV viral load is an important and clinically relevant parameter since patients 
with higher HCV viral loads have lower response rates to IFN and DAA based 
therapy60 (independent of IFNL4 status). Paradoxically, the “favourable” IFNL4 
variants have also been associated with both an increase in disease progression61 
and high viral load3,62; our data shows that site 2414 is one of the 11 sites that are 
putatively associated with IFNL4 genotypes. Further, our data shows that a decrease 
in viral load was only observed in those patients with the non-CC genotype whose 
virus carried the serine amino acid at site 2414 in NS5A protein. Since the 2414 S 
variant is found in 85% of non-CC patients (compared to 67% of CC patients), this 
interplay between host and viral genes helps explain the previous observation that 
non-CC patients have a lower HCV viral load (Figure 6). Our in vitro data from a 
genotype 3 replicon assay shows that a change from a serine to asparagine is 
associated with an increase in RNA replication and perhaps hyper-phosphorylation63, 
which is a negative regulator of virus replication.  
 
Our interpretation of the data (Figure 6) is that expression of IFNL4 by the 
“unfavourable” non-CC genotype leads to the activation of additional components of 
the immune response, likely driven by ISGs, which interact directly with specific 
amino acids in the viral genome (most notably amino acid 2414 in NS5A which has a 
significant impact on viral load (Figures 2b, 5 and S14)). Our data suggest that this 
also leads to an overall increase in the strength of purifying selection (decrease in 
dN/dS, Figure 4), and together this leads to lower viral load. However viruses that 
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establish chronic infections in non-CC patients have evolved to survive in the more 
hostile environment (for example mutating the serine at amino acid 2414 of NS5A), 
which makes them less likely to respond to interferon-based therapy. In contrast, our 
analysis suggests that the “favourable” CC genotype and the inactivation of IFNL4 
gene disables components of the immune response (therefore removing the effect of 
amino acid 2414 in NS5A on viral load), which leads to a reduced level of purifying 
selection (Figure 4). It is possible that this then permits a range of mutations which 
confer higher replicative fitness and therefore higher viral load (Figure S14), but 
these viruses are more susceptible to interferon-based treatments.  At the population 
level, we would expect a balance in the relative contribution of these mechanisms as 
viruses move between individuals with CC and non-CC genotypes. Our results make 
the prediction that the outcome of a new infection will be dependent on both the HLA 
alleles and the IFNL4 genotype of the patient who is the source of the new infection. 
Further analysis is required to fully understand the impact of CC and non-CC 
genotypes on the different components of the immune system and to establish their 
clinical relevance before, during and after infection. 
 
 
Figure 6: Overview of the observations relating to the interplay between innate 
immune response and the viral genome in hepatitis C virus (HCV) control. a) Infected 
individuals with IFNL4 CC genotype show high rates of spontaneous and treatment-
induced clearance of HCV. IFNL4 is not expressed, which in turn induces a weaker 
and possibly differential interferon-stimulated genes (ISG) expression. The host 
environment is associated with weaker purifying selection and allows viral mutations 
associated with a better replicative fitness to accumulate, leading to higher viral load. 
b) Infected individuals with IFNL4 non-CC genotype, have lower rates of 
spontaneous and treatment-induced clearance of HCV. IFNL4 is expressed and 
induces ISGs that collectively establish an antiviral state hostile to viral replication. 
This hostile environment induces a high selective pressure and fewer viral mutations 
can accumulate.  
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In conclusion, we provide a comprehensive genome-to-genome analysis in chronic 
HCV infections. Using this genome-wide, hypothesis-free, approach we show that 
the host’s HLA alleles leave multiple footprints in the HCV genome and that the 
host’s innate immune environment also influences the presence of amino acid 
polymorphism in the virus, both at specific loci, and genome-wide. We observe a 
common viral amino-acid residue that is associated with HCV viral load only in 
patients with the “unfavourable” non-CC IFNL4 genotype. These observations 
suggest that the innate and adaptive immune system jointly impact on HCV genome 
evolution and likely together determine the establishment of infection and its control 
over time. The new insights into the biological mechanisms that drive HCV evolution 
in vivo, and the identification of specific interactions between viral and host 
polymorphisms, are relevant for future approaches to treatment stratification and 
vaccine development. 
  
	 20	
Materials & Correspondence.  
Correspondence and material requests should be addressed to Chris Spencer 
(chris.spencer@well.ox.ac.uk) or by contacting STOP-HCV http://www.stop-
hcv.ox.ac.uk/contact . 
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Online Methods  
Patients and sample 
Plasma and DNA samples came from patients enrolled in the Boson study. Boson 
study is a phase 3 randomized open-label trial to determine the efficacy and safety of 
sofosbuvir with and without pegylated-interferon-alfa, in treatment-experienced 
patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and 
treatment-naïve or -experienced patients with HCV genotype 3 infection30. All 
patients provided written informed consent before undertaking any study-related 
procedures. The study protocol was approved by each institution’s review board or 
ethics committee before study initiation. The study was conducted in accordance with 
the International Conference on Harmonization Good Clinical Practice Guidelines 
and the Declaration of Helsinki. The study reported here is not a clinical trial, but is 
based on the analysis of patients from a clinical trial registration number: 
NCT01962441.  Sample sizes were determined by the available data. All samples for 
which both viral sequencing and host genetics were available were included in the 
final analysis unless otherwise specified. 
Host genotyping and imputation 
Informed consent for host genetic analysis was obtained from 567 patients. 
Genotyping was performed using Affymetrix UK Biobank arrays. We imputed the 
MHC class I loci HLA-A, HLA-B, HLA-C and class II loci HLA-DQA1, HLA-DQB1, 
HLA-DPB1, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 using HLA*IMP:0227 
accessed 22 March 2015.  HLA amino acids were also imputed by SNP2HLA64 using 
the T1DGC as the reference panel, which contains 5225 unrelated individuals 
(10,450 haplotypes). Logistic regression using posterior genotype probabilities (allele 
dosages) for each HLA allele from SNP2HLA were carried out using PLINK232 
(https://www.cog-genomics.org/plink2). 
Virus sequencing 
Sample collection and preparation 
RNA was isolated from 500µl plasma using the NucliSENS magnetic extraction 
system (bioMerieux) and collected in 30µl of kit elution buffer for storage in aliquots 
at -80°C. 
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Sequencing library construction, enrichment and sequencing 
Libraries were prepared for Illumina sequencing using the NEBNext® Ultra™ 
Directional RNA Library Prep Kit for Illumina® (New England Biolabs) with 5µl 
sample (maximum 10ng total RNA) and previously published modifications of the 
manufacturer’s guidelines (v2.0)23, briefly: fragmentation for 5 minutes at 94°C, 
omission of Actinomycin D at first-strand reverse transcription, library amplification 
for 18 PCR cycles using custom indexed primers65 and post-PCR clean-up with 
0.85× volume Ampure XP (Beckman Coulter). 
 
Libraries were quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen) 
and analysed using Agilent TapeStation with D1K High Sensitivity kit (Agilent) for 
equimolar pooling, then re-normalized by qPCR using the KAPA SYBR® FAST 
qPCR Kit (Kapa Biosystems) for sequencing.  A 500ng aliquot of the pooled library 
was enriched using the xGen® Lockdown® protocol from IDT (Rapid Protocol for 
DNA Probe Hybridization and Target Capture Using an Illumina TruSeq® or Ion 
Torrent® Library (v1.0), Integrated DNA Technologies) with equimolar-pooled 120nt 
DNA oligonucleotide probes (IDT) followed by a 12-cycle, modified, on-bead, post-
enrichment PCR re-amplification. The cleaned post-enrichment ve-Seq library was 
normalized with the aid of qPCR and sequenced with 151b paired-end reads on a 
single run of the Illumina MiSeq using v2 chemistry. 
Sequence data analysis 
De-multiplexed sequence read-pairs were trimmed of low-quality bases using 
QUASR v7.012066 and adapter sequences with CutAdapt version 1.7.167 and 
subsequently discarded if either read had less than 50b remaining sequence or if 
both reads matched the human reference sequence using Bowtie version 2.2.468. 
The remaining read pool was screened against a BLASTn database containing 165 
HCV genomes69 covering its diversity both to choose an appropriate reference and to 
select those reads which formed a majority population for de novo assembly with 
Vicuna v1.370 and finishing with V-FAT v1.0 (http://www.broadinstitute.org/scientific-
community/science/projects/viral-genomics/v-fat). Population consensus sequence at 
each site is defined as the most common variant at that site among all the patients. 
Phylogenetic and ancestral sequence reconstruction 
Whole genome viral consensus sequences for each patient were aligned using 
MAFFT71 with default settings. This alignment was used to create a maximum 
likelihood tree using RAxML72, assuming a general time reversible model of 
nucleotide substitution under the gamma model of rate heterogeneity. The resulting 
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tree was rooted at midpoint. Maximum likelihood ancestral sequence reconstruction 
was performed using RAxML72 with the maximum likelihood tree and HCV 
polyprotein sequences as input.  
Association analysis 
To test for association between human SNPs and HCV amino acids at genome-to-
genome level, we performed logistic regression using PLINK232 (https://www.cog-
genomics.org/plink2) adjusted for the human population structure (three first PCs 
assessed using EIGENSOFT v3.073) and the virus population structure (10 first PCs). 
For the viral data PCA was performed on the nucleotide data. Tri and quad-allelic 
sites were converted to binary variables and the amino acid frequencies were 
standardised to have mean zero and unit variance. MATLAB (Release 2015a, The 
MathWorks) was used to perform the PCA using the singular value decomposition 
function.  
 
To test for association between imputed HLA alleles and HCV amino acids, we used 
Fisher’s exact test, correcting for the virus population structure as described in 
Bhatacharaya et al.42. We used the inferred ancestral amino acid to construct a 2x4 
contingency table where rows denote presence or absence of a host HLA allele, and 
the columns denote changes to and away from a specific amino acid in viruses with 
and without the amino acid inferred to be ancestral. To test for association between 
IFNL4 SNP rs12979860 genotypes and HCV amino acids, we used the same 
Fisher’s exact test with a dominant model for IFNL4 rs12979860 by encoding 
genotypes as CC and non-CC. 
 
Permutation was used to estimate the FDR for association tests that used Fisher’s 
exact test. The labels (presence and absence of each HLA allele or the INFL4 
genotypes) were randomly permuted 500 times and in each case the p-values of the 
associations were calculated. For each threshold t, the expectation of the number of 
false positives was estimated from result of the permutation tests. FDR for threshold t 
was then defined as the expected number of false positives divided by the observed 
number of significant associations in the actual data at threshold t. 
 
To test for enrichment of association signals in epitope regions, viral proteins or with 
a specific HLA allele we used Fisher’s exact test. Each site is either within a target 
region (epitope regions or a specific viral protein) or not and the most associated test 
with it, is significant or not with an FDR of 5%. The resulting contingency table was 
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tested using Fisher’s exact test to assess enrichment or depletion of signals of 
association. 
 
To assess the relationship between rates of escape and reversion in HLA 
presentation, we estimated the odds ratio for each 2x2 sub-table used in the Fisher’s 
exact test. This was done only for viral sites associated with HLA alleles at 20% FDR 
and which there were sufficient observations in both tables to estimate the odds ratio 
where confidence interval did not go to infinity. Pearson’s correlation coefficient was 
used to assess the relationship between the log10(OR) of escape and reversion. 
 
To test for enrichment of viral amino acid associations with host IFNL4 genotypes in 
viral proteins, the null distribution of number of association in each protein was 
estimated using 10,000 permutations of IFNL4 labels and performing the same tests. 
The estimated null distribution of number of associations for each viral protein was 
compared to the observed number of associations in the data to test for enrichment 
or depletion of number of associations. To test if HVR1, HVR2, HVR3, ISDR and 
PKR-BD regions show differences in the number of changes away from the 
population consensus in CC and non-CC hosts, we used a Poisson regression. In 
each individual and each locus we determined the number of differences to the 
population consensus. We then estimated the effect of INFL4 genotypes on the 
mean number of differences to the population consensus using Poisson regression. 
The same procedure was used to test if the total number of differences across the 
whole poly-protein relative to the population consensus was influenced by INFL4 
genotypes. 
 
To estimate the rate of synonymous and non-synonymous mutations, we used 
dndsml function from MATLAB (Release 2015a, The MathWorks) that uses Goldman 
and Yang’s method. It estimates (using maximum likelihood) an explicit model for 
codon substitution that takes into account transition/transversion rate bias and 
base/codon frequency bias. Then it uses the model to correct synonymous and non-
synonymous counts to account for multiple substitutions at the same site. To 
estimate dN and dS, each sequence was compared to the population consensus 
which indicates the most common nucleotide observed in our data set at each 
position along the genome. 
 
To determine whether IFNL4 genotypes impact on HLA alleles presentation of 
epitopes, logistic regression with interaction term was used. The outcome for 
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individuals was whether on the terminal branches of the tree a specific had changed 
amino or not. We tested for interaction between presence and absence of the 
associated HLA allele and IFNL4 genotypes for all combinations of HLA alleles and 
viral sites associated at a 20% FDR. In addition, we tested for an overall effect of 
INFL4 genotypes on HLA alleles’ presentation of epitopes. We used our 2x4 
contingency tables and the odds ratios estimated from the 2x2 sub-tables to infer the 
antigenic amino acids. If the odds ratio indicates that in individuals with HLA allele 
present, the "X ancestral amino acid -> any other amino acid" element is enriched 
relative to individuals without the HLA allele then we assume the X amino acid is the 
antigenic amino acid and escape occurs away from X to any other amino acid. For 
these cases, we count how many of "X ancestral amino acid -> any other amino acid" 
occur in CC and non-CC individuals across all combinations of HLA alleles and viral 
sites associated at 20% FDR. If IFNL4 genotypes have no impact on the HLA 
presentation (null hypothesis), then the mean number of escape mutations in CC and 
non-CC hosts should be proportional to the frequency of hosts with CC and non-CC 
genotypes (null distribution is binomial with parameters n equal to the total number of 
observed escape mutations and p equal to the proportion of CC hosts).  
 
We used linear regression in PLINK232 (https://www.cog-genomics.org/plink2) to test 
for association between human SNPs and log10 transformed pre-treatment  viral load 
(PTVL) including sex and first three PCs of the host genome as covariates. We used 
linear regression to test for association between HCV amino acids (with a minimal 
count of 10 at each site) and viral load. We used linear regression in R (version 3.2.4 
(2016-03-10))74 to analyse the interaction between IFNL4 genotypes and amino 
acids at viral site 2414 and to quantify their impact on viral load. 
 
For all viral sites associated with IFNL4 genotypes at 20% FDR, we assessed if there 
is a relationship between effect size of non-consensus amino acids on viral load and 
effect size of IFNL4 genotypes and changes to non-consensus amino acids. We 
estimated the odds ratio of enrichment of changes away from the consensus amino 
acid on the terminal branches of the virus tree. We also estimated the effect size of 
non-consensus amino acids on the log10 of viral load using a linear regression with 
IFNL4 genotype as a covariate. Additionally, we estimated the effect size of non-
consensus amino acid on the log10 viral load in CC and non-CC hosts. We used 
Pearson’s correlation coefficient to measure the strength of relationship between the 
effect size of non-consensus amino acids on viral load and log of odds ratio of 
enrichment of non-consensus amino acid changes in CC hosts. 
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Data	and	Code	Availability	
The consensus viral sequences will be made available via GENBANK 
(http://www.ncbi.nlm.nih.gov/genbank/ ), and the human genotype data will be made 
available via EGA (https://www.ebi.ac.uk/ega/ ) through the STOP-HCV data access 
committee http://www.stop-hcv.ox.ac.uk. R and MATLAB code used to generate the 
results and figures from the primary analyses described above are available from the 
authors on request. 
Replication study 
To replicate the IFNL4 SNP rs12979860 results, we ran the association analysis on 
an independent HCV infected population	that was recruited to the FISSION, FUSION 
and POSITRON phase 3 clinical studies75,76 . Paired human genome-wide 
genotyping and HCV sanger sequencing data for NS5B amplicon were obtained from 
DNA and plasma samples collected from 360 Caucasian patients chronically infected 
with HCV genotype 2 (N=153) or 3 (N=208). We searched for association between 
the IFNL4 SNP rs12979860 and viral position 2570 using logistic regression and a 
binary vector as the outcome which indicated the presence or absence of amino acid 
V for all samples at position 2570. To prevent spurious associations due to host and 
viral stratification, we included human principal components and viral genotype as 
covariates.  
Replicon assay 
Cell Culture 
Huh7.5-Sec14L2 cells, previously reported53 were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies) supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 0 enicillin, 100  100 lmM HEPES 
and 0.1M nonessential amino acids as described77. Huh7.5 cells are heterozygous 
CT for the IFNL4 rs12979860 SNP78. 
HCV Mutant Replicons 
The enhanced version of the subgenomic replicon of genotype 3a strain S52, lacking 
of neomycin resistance gene, has been previously described53. Site-specific 
mutations were introduced using QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent Technologies) following manufacturer instructions and confirmed by direct 
sequencing. HCV mutant plasmids were linearized by XbaI digestion (New England 
Biolabs; NEB), mung-bean treated (NEB) and purified. Linearized DNA was then 
used as template for in vitro RNA transcription (IVT) (Megascript T7, Life 
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Technologies) according to manufacturer protocol. Finally, IVT RNA has been 
DNAse treated, purified and stored at -80°C. 
Electroporation and Luciferase Detection 
For electroporation, cells were counted and then washed twice in ice-cold PBS. 
Typically, for each mutant 4x106 cells were mixed with 1 µg of replicon RNA in a 
4mm cuvette and electroporated in the Gene Pulser Xcell (Bio-Rad) at 250 V, 950 µF 
using exponential decay setting. Cells were immediately recovered in pre-warmed 
complete DMEM, seeded in a 24-well plate and incubated at 37°C. After 5, 24, 48 or 
72 hours, medium was removed and cells lysed with Glo Lysis Buffer (Promega). 
Cell lysates were then transferred in a white 96-well plate (Corning) and the 
luciferase expression was quantitated in a luminometer (GloMax 96 Microplate 
Luminometer, Promega) using Bright-Glo assay system (Promega). 
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Table 1. Associations between HLA alleles and viral amino acids at a 5% false 
discovery rate. For each combination of HLA allele and viral site, only the most 
significant associated amino acid is reported. The first amino acid at “variable amino 
acids at this site” column indicates the most common amino acid at the site in our 
data. 
HLA allele 
HCV 
amino acid 
position 
Viral 
protein 
Variable 
amino acids 
at this site 
Associated 
amino acid P q value 
In a 
known 
epitope? 
B*07:02 42 C PL P 1.55x10-07 5.00x10-03 Yes 
C*07:02 42 C PL P 2.27x10-07 6.10x10-03 Yes 
C*15:02 561 E2 VTLI L 5.70x10-07 1.50x10-02 No 
A*31:01 1270 NS3 RKHS H 4.21x10-10 < 4.00x10-04 Yes 
A*33:03 1282 NS3 NVTSA T 1.73x10-07 5.26x10-03 Yes 
B*15:01 1290 NS3 KPARS R 1.25x10-07 4.47x10-03 Yes 
A*68:02 1341 NS3 VA V 2.43x10-09 4.44x10-04 No 
A*68:02 1344 NS3 TVA T 3.68x10-10 < 4.00x10-04 No 
B*51:01 1380 NS3 ILV L 3.22x10-08 1.67x10-03 Yes 
A*01:01 1444 NS3 FY F 9.63x10-33 < 4.00x10-04 Yes 
A*68:02 1452 NS3 IV I 6.98x10-09 4.44x10-04 No 
A*30:02 1585 NS3 YF Y 1.19x10-06 3.28x10-02 No 
B*13:02 1635 NS3 ITVLAF T 7.38x10-08 3.13x10-03 No 
B*08:01 1646 NS3 MTAVSI T 2.89x10-12 < 4.00x10-04 No 
C*07:01 1646 NS3 MTAVSI T 3.01x10-07 7.39x10-03 No 
DQA1*05:01 1646 NS3 MTAVSI T 7.24x10-07 1.76x10-02 No 
A*02:01 1873 NS4B LFKICVPRMTA F 4.06x10
-10 < 4.00x10-04 No 
B*38:01 2034 NS5A STNLPIAQVDKEMGRFW P 7.56x10
-08 3.13x10-03 Yes 
B*18:01 2144 NS5A ED E 1.16x10-06 3.28x10-02 Yes 
A*31:01 2510 NS5B AKQSEMGLTV A 4.96x10
-08 2.14x10-03 No 
A*32:01 2537 NS5B NDHSYEAI N 1.13x10-08 7.27x10-04 Yes 
A*32:01 2540 NS5B RSKHNQC R 7.45x10-09 6.00x10-04 Yes 
A*02:11 2600 NS5B QKRSAL Q 1.01x10-06 3.12x10-02 Yes 
A*26:01 2605 NS5B EAGVK G 2.61x10-07 6.64x10-03 Yes 
 
 
 
Variable	 		
Age	in	years	(Mean	(range))	 49.8	(19-73)	
log10	pre	treatment	viral	load	(Mean	(range))	 6.3	(3.9-7.6)	
Self	reported	ethnicity	(N	(%))	 		
White	 452	(83.2%)	
Asian	 74	(13.8	%)	
Other	 16	(2.9%)	
Sex	(N	(%)))	 		
Female	 177	(32.6%)	
Male	 365	(67.4%)	
IFNL4	SNP	rs12979860	(N	(%))	 		
CC	 206	(38.1%)	
TC	 264	(48.6%)	
TT	 72	(13.3%)	
HCV	genotype	 	
													3a	 487	(89.9%)	
													3	non	a	 9	(1.6%)	
													2	 46	(8.5%)	
	
Table	S1.	Demographic	and	clinical	data	of	the	cohort.		
	
Figure	S1.	Ancestry	stratifies	patterns	of	human	genetic	variation.	PCA	plots	(1st,	2nd	and	3rd	components)	estimated	from	human	genotypes.	 Individuals	are	coloured	 by	 self-reported	 population	 of	 origin.	 Because	 of	 the	 over-representation	 of	 individuals	 from	 the	 respective	 populations,	 the	 1st	 and	 2nd	components	 differentiate	 South	Asian	 (Pakistan,	 India)	 and	Western	 European	patients,	while	the	3rd	component	differentiates	a	small	number	of	patients	with	African	ancestry	from	the	other	populations.	
		
Self reported ethnicity
HLA	allele	 Asian	(%)	 White	(%)	 P	(Fisher)	
DQB1*06:01	 19	 0.66	 1.83E-10	
DRB1*15:02	 16	 0.66	 8.49E-09	
C*12:02	 15	 0.88	 1.84E-07	
B*52:01	 14	 0.88	 1.09E-06	
B*40:06	 9.5	 0.22	 6.01E-06	
B*13:01	 8.1	 0	 6.48E-06	
A*02:01	 20	 48	 7.48E-06	
B*07:02	 5.4	 28	 7.64E-06	
B*44:02	 2.7	 22	 1.17E-05	
A*11:01	 34	 13	 1.96E-05	
A*02:11	 6.8	 0	 4.89E-05	
C*05:01	 2.7	 20	 5.43E-05	
DPA1*02:02	 22	 6.2	 8.48E-05	
DRB1*01:01	 1.4	 16	 1.10E-04	
DQA1*01:03	 30	 12	 2.37E-04	
A*33:03	 6.8	 0.22	 2.61E-04	
DRB1*12:02	 6.8	 0.22	 2.61E-04	
C*04:03	 5.4	 0	 3.65E-04	
C*03:02	 6.8	 0.44	 8.13E-04	
DQB1*06:02	 11	 28	 9.12E-04	
DRB1*10:01	 11	 2.2	 1.44E-03	
C*08:01	 5.4	 0.22	 1.63E-03	
C*15:02	 14	 3.8	 1.92E-03	
DPA1*01:03	 88	 97	 2.11E-03	
A*02:06	 4.1	 0	 2.69E-03	
B*15:02	 4.1	 0	 2.69E-03	
C*07:01	 14	 30	 3.07E-03	
DRB1*14:04	 6.8	 0.88	 3.87E-03	
B*51:01	 20	 8.4	 5.43E-03	
A*26:01	 14	 4.6	 6.21E-03	
C*16:02	 5.4	 0.66	 9.10E-03	
DQA1*06:01	 5.4	 0.66	 9.10E-03	
C*14:02	 9.5	 2.7	 1.02E-02	
C*08:02	 0	 7.1	 1.47E-02	
C*02:02	 1.4	 9.3	 1.96E-02	
B*27:07	 2.7	 0	 1.96E-02	
B*46:01	 2.7	 0	 1.96E-02	
DQA1*03:01	 18	 30	 2.63E-02	
DRB1*04:01	 5.4	 15	 2.71E-02	
A*03:01	 15	 27	 2.99E-02	
DRB3*01:01	 15	 27	 2.99E-02	
B*27:05	 1.4	 8.6	 3.01E-02	
A*31:01	 12	 5.3	 3.56E-02	
B*14:02	 0	 5.3	 3.58E-02	
HLA	allele	 Asian	(%)	 White	(%)	 P	(Fisher)	
B*35:03	 8.1	 2.9	 3.80E-02	
DQA1*01:02	 27	 40	 3.94E-02	
A*68:01	 12	 5.5	 4.09E-02	
A*23:01	 0	 5.1	 5.90E-02	
B*15:17	 4.1	 0.88	 6.15E-02	
DQB1*05:02	 11	 5.1	 6.26E-02	
B*15:01	 2.7	 9.3	 6.80E-02	
DRB3*02:10	 1.4	 6.9	 6.86E-02	
DPA1*02:01	 38	 27	 6.95E-02	
B*35:02	 5.4	 2	 9.55E-02	
A*24:07	 2.7	 0.44	 9.70E-02	
DRB1*04:04	 2.7	 8.8	 1.01E-01	
C*07:04	 1.4	 6.4	 1.03E-01	
A*01:01	 23	 33	 1.05E-01	
DQB1*03:02	 12	 21	 1.12E-01	
DRB1*04:03	 4.1	 1.3	 1.20E-01	
A*02:07	 1.4	 0	 1.41E-01	
A*26:03	 1.4	 0	 1.41E-01	
A*34:01	 1.4	 0	 1.41E-01	
A*74:01	 1.4	 0	 1.41E-01	
B*15:13	 1.4	 0	 1.41E-01	
B*27:04	 1.4	 0	 1.41E-01	
C*03:06	 1.4	 0	 1.41E-01	
DPA1*03:01	 1.4	 0	 1.41E-01	
DPA1*04:01	 1.4	 0	 1.41E-01	
DQB1*04:01	 1.4	 0	 1.41E-01	
DRB1*11:02	 1.4	 0	 1.41E-01	
DQB1*02:02	 24	 17	 1.47E-01	
DRB1*16:02	 2.7	 0.66	 1.47E-01	
DRB3*03:01	 32	 24	 1.51E-01	
C*16:01	 1.4	 5.5	 1.54E-01	
A*29:02	 1.4	 5.8	 1.54E-01	
DQA1*04:01	 1.4	 6	 1.57E-01	
DRB1*15:01	 22	 30	 1.67E-01	
B*40:01	 14	 8.6	 1.95E-01	
DRB1*08:01	 1.4	 4.9	 2.29E-01	
B*38:01	 0	 3.1	 2.36E-01	
DRB1*13:01	 16	 11	 2.41E-01	
DRB5*99:01	 95	 98	 2.46E-01	
A*03:02	 1.4	 0.22	 2.62E-01	
B*35:20	 1.4	 0.22	 2.62E-01	
B*38:02	 1.4	 0.22	 2.62E-01	
B*48:01	 1.4	 0.22	 2.62E-01	
DRB1*15:03	 1.4	 0.22	 2.62E-01	
HLA	allele	 Asian	(%)	 White	(%)	 P	(Fisher)	
DQB1*05:01	 15	 21	 2.74E-01	
B*08:01	 16	 22	 2.86E-01	
C*01:02	 9.5	 6.2	 3.12E-01	
B*50:01	 2.7	 1.3	 3.13E-01	
DRB3*02:02	 59	 53	 3.15E-01	
B*18:01	 4.1	 8	 3.38E-01	
B*35:08	 1.4	 0.44	 3.66E-01	
DRB1*08:03	 1.4	 0.44	 3.66E-01	
DRB1*09:01	 2.7	 1.5	 3.68E-01	
DRB4*01:01	 41	 47	 3.79E-01	
DRB1*11:01	 12	 8.6	 3.81E-01	
DQA1*02:01	 30	 25	 3.87E-01	
DRB1*07:01	 30	 25	 3.87E-01	
A*25:01	 0	 2.7	 3.90E-01	
B*58:01	 4.1	 2.2	 4.08E-01	
DRB1*13:02	 4.1	 6.9	 4.54E-01	
B*47:01	 1.4	 0.66	 4.56E-01	
DRB5*01:01	 24	 29	 4.87E-01	
DRB5*02:02	 5.4	 3.8	 5.18E-01	
C*06:02	 22	 18	 5.22E-01	
B*41:01	 1.4	 0.88	 5.33E-01	
B*53:01	 1.4	 0.88	 5.33E-01	
DRB1*08:02	 1.4	 0.88	 5.33E-01	
DRB1*11:04	 5.4	 4	 5.33E-01	
B*13:02	 5.4	 4.2	 5.49E-01	
DQB1*06:03	 14	 12	 5.65E-01	
B*37:01	 6.8	 5.1	 5.74E-01	
B*45:01	 1.4	 1.1	 5.99E-01	
B*56:01	 1.4	 1.1	 5.99E-01	
C*17:01	 1.4	 1.1	 5.99E-01	
DPA1*01:04	 1.4	 1.1	 5.99E-01	
B*39:06	 0	 1.5	 6.01E-01	
A*02:05	 0	 1.8	 6.08E-01	
A*30:02	 0	 1.8	 6.08E-01	
A*68:02	 0	 1.8	 6.08E-01	
B*14:01	 0	 1.8	 6.08E-01	
B*39:01	 0	 1.8	 6.08E-01	
B*49:01	 0	 1.8	 6.08E-01	
DRB1*04:02	 0	 1.8	 6.08E-01	
DRB1*04:07	 0	 1.8	 6.08E-01	
DRB1*13:03	 0	 1.8	 6.08E-01	
DRB1*01:02	 0	 2	 6.21E-01	
DRB1*12:01	 0	 2	 6.21E-01	
C*12:03	 8.1	 6.9	 6.29E-01	
HLA	allele	 Asian	(%)	 White	(%)	 P	(Fisher)	
DQB1*05:03	 9.5	 7.5	 6.38E-01	
B*35:01	 9.5	 8	 6.48E-01	
C*03:03	 6.8	 9.1	 6.59E-01	
DQA1*01:01	 26	 29	 6.77E-01	
DQA1*05:01	 43	 41	 7.05E-01	
DRB1*01:03	 1.4	 3.1	 7.06E-01	
DRB1*16:01	 1.4	 3.1	 7.06E-01	
DQB1*02:01	 27	 25	 7.75E-01	
DQB1*03:01	 28	 27	 7.78E-01	
DQB1*04:02	 4.1	 5.8	 7.84E-01	
C*07:02	 28	 31	 7.85E-01	
DRB4*99:01	 92	 90	 8.31E-01	
B*44:03	 11	 10	 8.37E-01	
C*03:04	 11	 12	 8.48E-01	
A*24:02	 16	 17	 8.70E-01	
DRB1*03:01	 26	 25	 8.86E-01	
DRB3*99:01	 55	 56	 9.00E-01	
A*69:01	 0	 0.88	 1.00E+00	
B*15:18	 0	 0.88	 1.00E+00	
DRB1*11:03	 1.4	 1.3	 1.00E+00	
A*01:02	 0	 0.22	 1.00E+00	
A*11:02	 0	 0.22	 1.00E+00	
A*24:03	 0	 0.22	 1.00E+00	
A*66:01	 0	 0.22	 1.00E+00	
A*80:01	 0	 0.22	 1.00E+00	
B*07:05	 0	 0.22	 1.00E+00	
B*15:04	 0	 0.22	 1.00E+00	
B*15:20	 0	 0.22	 1.00E+00	
B*15:30	 0	 0.22	 1.00E+00	
B*39:24	 0	 0.22	 1.00E+00	
B*44:05	 0	 0.22	 1.00E+00	
B*81:01	 0	 0.22	 1.00E+00	
C*15:04	 0	 0.22	 1.00E+00	
DQA1*01:04	 0	 0.22	 1.00E+00	
DQA1*05:05	 0	 0.22	 1.00E+00	
DQB1*03:04	 0	 0.22	 1.00E+00	
DQB1*05:04	 0	 0.22	 1.00E+00	
DRB1*08:04	 0	 0.22	 1.00E+00	
DRB1*14:03	 0	 0.22	 1.00E+00	
DRB1*14:44	 0	 0.22	 1.00E+00	
DRB1*14:01	 5.4	 6.6	 1.00E+00	
A*32:01	 6.8	 7.1	 1.00E+00	
DQB1*06:04	 4.1	 5.1	 1.00E+00	
B*40:02	 1.4	 2.4	 1.00E+00	
HLA	allele	 Asian	(%)	 White	(%)	 P	(Fisher)	
C*04:01	 18	 17	 1.00E+00	
DQB1*03:03	 8.1	 9.3	 1.00E+00	
A*33:01	 0	 1.3	 1.00E+00	
B*55:01	 5.4	 6	 1.00E+00	
B*57:01	 5.4	 6	 1.00E+00	
A*30:01	 2.7	 3.1	 1.00E+00	
DQB1*06:09	 1.4	 2.7	 1.00E+00	
DRB1*04:05	 1.4	 1.5	 1.00E+00	
A*30:04	 0	 0.66	 1.00E+00	
B*41:02	 0	 0.66	 1.00E+00	
A*29:01	 0	 0.44	 1.00E+00	
A*34:02	 0	 0.44	 1.00E+00	
B*15:03	 0	 0.44	 1.00E+00	
B*27:02	 0	 0.44	 1.00E+00	
B*51:08	 0	 0.44	 1.00E+00	
C*16:04	 0	 0.44	 1.00E+00	
DRB1*04:11	 0	 0.44	 1.00E+00	
DRB1*13:05	 0	 0.44	 1.00E+00		
Table	S2.	HLA	 frequencies	 in	 the	 two	main	self	 reported	ethnic	groups	 in	
the	cohort.	We	performed	Fisher’s	exact	test	to	determine	association	between	ethnicity	and	each	HLA	allele.	The	table	is	ordered	by	the	p	value	of	the	Fisher’s	exact	test.	The	p	value	is	not	corrected	for	multiple	testing.	
	
	
	
	
	
	
		
			
Figure	 S2.	 Virus	 whole-genome	 phylogeny	 labeled	 by	 self-reported	
ethnicity	for	all	patients.	Maximum-likelihood	phylogenetic	tree	was	estimated	from	virus	whole-genome	sequences	using	RAxML	software	with	a	general	time	reversible	 substitution	 model	 incorporating	 a	 gamma	 model	 of	 rate	heterogeneity	 and	 a	 constrained	 guide	 tree.	 The	 resulting	 tree	 was	 mid-point	rooted.		The	tips	of	the	tree	are	coloured	by	self	reported	host	ethnicities.	White,	Asian	and	others	are	coloured	respectively	as	 red,	blue	and	grey	on	 the	 tips	of	the	tree.		
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Figure	 S3.	 PCA	 of	 the	 virus	 nucleotides	 is	 associated	 with	 HCV	 subtypes.	PCA	 plots	 (1st	 to	 10th	 components)	 estimated	 from	 virus	 whole-genome	sequences.	 HCV	 genotypes	 were	 inferred	 by	 comparing	 sequences	 with	 HCV	whole	genome	reference	sequences.	Blue	dots	represent	HCV	genotype	3	(circles	represent	 subtype	 3a,	 triangles	 subtype	 3b,	 square	 represents	 subtype	 3g,	crosses	 represent	 subtype	 3i);	 green	 dots	 represent	 genotype	 2	 (circles	represent	subtype	2a,	triangles	subtype	2b,	squares	represent	subtype	2c,	cross	represents	subtype	2m);	the	red	circle	represents	the	1a/2b	recombinant	isolate.									
	Figure	S4.	QQplot	for	genome-to-genome	analysis.	Top	panel)	No	adjustment	for	 population	 structure.	 Bottom	 panel)	 Adjusted	 for	 human	 (first	 3	 PCs)	 and	virus	(first	10	PCs)	population	structures				
Human	
SNP	rsID	 Chromosome	 Position	 P	
Associated	
viral	
amino	acid	
variant	
Viral	gene	
rs3129073	 6	 29615822	 2.42E-19	 F_1444	 NS3	
rs3117289	 6	 29609921	 2.92E-19	 F_1444	 NS3	
rs29228	 6	 29623739	 3.32E-19	 F_1444	 NS3	
rs1610742	 6	 29677952	 6.93E-19	 F_1444	 NS3	
rs3129039	 6	 29658864	 7.54E-19	 F_1444	 NS3	
rs1632962	 6	 29683808	 8.19E-19	 F_1444	 NS3	
rs3129063	 6	 29645613	 9.57E-19	 F_1444	 NS3	
rs1633063	 6	 29726046	 1.44E-18	 F_1444	 NS3	
rs1632964	 6	 29682239	 1.84E-18	 F_1444	 NS3	
rs1610601	 6	 29700183	 2.32E-18	 F_1444	 NS3	
rs3117295	 6	 29653377	 3.22E-18	 F_1444	 NS3	
rs1736922	 6	 29693969	 3.50E-18	 F_1444	 NS3	
rs29218	 6	 29607429	 3.59E-18	 F_1444	 NS3	
rs1628578	 6	 29695502	 4.32E-18	 F_1444	 NS3	
rs1736915	 6	 29704316	 3.20E-17	 F_1444	 NS3	
rs1633005	 6	 29764472	 4.22E-17	 F_1444	 NS3	
rs1633096	 6	 29707267	 8.13E-17	 F_1444	 NS3	
rs2107203	 6	 29669830	 1.95E-16	 F_1444	 NS3	
rs3129066	 6	 29668537	 2.45E-16	 F_1444	 NS3	
rs375984	 6	 29644502	 2.50E-16	 F_1444	 NS3	
rs1633088	 6	 29713580	 2.57E-16	 F_1444	 NS3	
rs2535238	 6	 29645038	 3.10E-16	 F_1444	 NS3	
rs3117301	 6	 29654700	 3.15E-16	 F_1444	 NS3	
rs2747421	 6	 29645118	 3.77E-16	 F_1444	 NS3	
rs3129055	 6	 29670261	 3.87E-16	 F_1444	 NS3	
rs1611350	 6	 29698821	 4.11E-16	 F_1444	 NS3	
rs2747460	 6	 29657127	 4.37E-16	 F_1444	 NS3	
rs356971	 6	 29979797	 4.76E-16	 F_1444	 NS3	
rs1633021	 6	 29746869	 4.99E-16	 F_1444	 NS3	
rs3116803	 6	 29667872	 5.20E-16	 F_1444	 NS3	
rs1264709	 6	 30056476	 1.91E-15	 F_1444	 NS3	
rs3129012	 6	 29988642	 2.21E-15	 F_1444	 NS3	
rs2523971	 6	 29938258	 4.74E-15	 F_1444	 NS3	
rs1611133	 6	 29809382	 6.89E-15	 F_1444	 NS3	
rs1611136	 6	 29811131	 7.40E-15	 F_1444	 NS3	
rs2844796	 6	 30072511	 9.92E-15	 F_1444	 NS3	
rs3131865	 6	 29672165	 1.10E-14	 F_1444	 NS3	
rs9257794	 6	 29335661	 1.47E-14	 F_1444	 NS3	
rs2508049	 6	 29823883	 1.94E-14	 F_1444	 NS3	
rs2517862	 6	 29821937	 2.23E-14	 F_1444	 NS3	
rs259940	 6	 30011934	 2.59E-14	 F_1444	 NS3	
rs2734970	 6	 29834472	 2.70E-14	 F_1444	 NS3	
rs356967	 6	 29973910	 3.03E-14	 F_1444	 NS3	
rs401618	 6	 29950210	 3.23E-14	 F_1444	 NS3	
rs2735067	 6	 29951106	 3.82E-14	 F_1444	 NS3	
rs6934993	 6	 29337500	 4.01E-14	 F_1444	 NS3	
rs356968	 6	 29975047	 4.27E-14	 F_1444	 NS3	
rs1150742	 6	 30028831	 4.86E-14	 F_1444	 NS3	
rs3094176	 6	 29821270	 5.22E-14	 F_1444	 NS3	
rs3129683	 6	 29286670	 6.85E-14	 F_1444	 NS3	
rs1245371	 6	 30038352	 7.30E-14	 F_1444	 NS3	
rs259943	 6	 30015330	 7.42E-14	 F_1444	 NS3	
rs1610682	 6	 29801324	 9.01E-14	 F_1444	 NS3	
rs1264697	 6	 30067568	 1.10E-13	 F_1444	 NS3	
rs2734986	 6	 29818568	 2.09E-13	 F_1444	 NS3	
rs1110446	 6	 30070937	 2.24E-13	 F_1444	 NS3	
rs9258593	 6	 29819599	 2.67E-13	 F_1444	 NS3	
rs707910	 6	 29910663	 3.06E-13	 F_1444	 NS3	
rs1611635	 6	 29836463	 3.06E-13	 F_1444	 NS3	
rs2240071	 6	 30070932	 3.23E-13	 F_1444	 NS3	
rs1264702	 6	 30065575	 3.50E-13	 F_1444	 NS3	
rs1264703	 6	 30065416	 3.86E-13	 F_1444	 NS3	
rs413985	 6	 29894600	 4.05E-13	 F_1444	 NS3	
rs1655900	 6	 29916618	 4.14E-13	 F_1444	 NS3	
rs2523964	 6	 29939294	 4.83E-13	 F_1444	 NS3	
rs1611701	 6	 29827956	 5.66E-13	 F_1444	 NS3	
rs1630969	 6	 29765001	 6.81E-13	 F_1444	 NS3	
rs2523933	 6	 29932292	 7.28E-13	 F_1444	 NS3	
rs2734985	 6	 29818662	 8.64E-13	 F_1444	 NS3	
rs2517870	 6	 29818744	 9.01E-13	 F_1444	 NS3	
rs1736994	 6	 29766596	 9.28E-13	 F_1444	 NS3	
rs1633004	 6	 29764663	 1.01E-12	 F_1444	 NS3	
rs2734980	 6	 29821896	 1.07E-12	 F_1444	 NS3	
rs5013088	 6	 29820389	 1.07E-12	 F_1444	 NS3	
rs259919	 6	 30025503	 1.12E-12	 F_1444	 NS3	
rs1737041	 6	 29736229	 1.26E-12	 F_1444	 NS3	
rs1611208	 6	 29759885	 1.33E-12	 F_1444	 NS3	
rs1633041	 6	 29733223	 1.40E-12	 F_1444	 NS3	
rs1077433	 6	 29783064	 1.46E-12	 F_1444	 NS3	
rs2734984	 6	 29820831	 1.55E-12	 F_1444	 NS3	
rs1736959	 6	 29782470	 1.58E-12	 F_1444	 NS3	
rs1736963	 6	 29777983	 1.58E-12	 F_1444	 NS3	
rs885940	 6	 29739057	 1.58E-12	 F_1444	 NS3	
rs2517861	 6	 29821982	 1.80E-12	 F_1444	 NS3	
rs1116221	 6	 30071330	 1.94E-12	 F_1444	 NS3	
rs1736983	 6	 29768049	 2.10E-12	 F_1444	 NS3	
rs1610637	 6	 29739906	 2.11E-12	 F_1444	 NS3	
rs1611209	 6	 29759923	 2.11E-12	 F_1444	 NS3	
rs1632988	 6	 29772395	 2.14E-12	 F_1444	 NS3	
rs1615962	 6	 29745726	 2.19E-12	 F_1444	 NS3	
rs1736971	 6	 29776322	 2.25E-12	 F_1444	 NS3	
rs2734945	 6	 29855945	 2.58E-12	 F_1444	 NS3	
rs1108052	 6	 30069795	 2.59E-12	 F_1444	 NS3	
rs1629068	 6	 29765291	 2.61E-12	 F_1444	 NS3	
rs1632987	 6	 29772549	 2.71E-12	 F_1444	 NS3	
rs209181	 6	 28792477	 2.73E-12	 F_1444	 NS3	
rs1264695	 6	 30067892	 2.85E-12	 F_1444	 NS3	
rs259939	 6	 30011581	 4.69E-12	 F_1444	 NS3	
rs1632973	 6	 29777171	 5.51E-12	 F_1444	 NS3	
rs1610663	 6	 29778626	 6.13E-12	 F_1444	 NS3	
rs2523408	 6	 29778109	 6.21E-12	 F_1444	 NS3	
rs2765220	 6	 28769671	 9.11E-12	 F_1444	 NS3	
rs1610699	 6	 29778987	 9.95E-12	 F_1444	 NS3	
rs1610707	 6	 29782048	 1.42E-11	 F_1444	 NS3	
rs259938	 6	 30008003	 2.23E-11	 F_1444	 NS3	
rs1130356	 6	 29796327	 2.98E-11	 F_1444	 NS3	
rs1737049	 6	 29735104	 4.08E-11	 F_1444	 NS3	
rs445150	 6	 29646879	 5.05E-11	 F_1444	 NS3	
rs2747430	 6	 29648506	 5.35E-11	 F_1444	 NS3	
rs396660	 6	 29646165	 6.71E-11	 F_1444	 NS3	
rs1233495	 6	 29444121	 9.22E-11	 F_1444	 NS3	
rs9257182	 6	 28754817	 1.10E-10	 F_1444	 NS3	
rs1233487	 6	 29468809	 1.24E-10	 F_1444	 NS3	
rs916570	 6	 30066031	 1.24E-10	 F_1444	 NS3	
rs2844531	 6	 31353171	 1.53E-10	 T_1646	 NS3	
rs1633030	 6	 29745794	 1.58E-10	 F_1444	 NS3	
rs2735042	 6	 29747373	 1.58E-10	 F_1444	 NS3	
rs1233367	 6	 29622220	 1.62E-10	 F_1444	 NS3	
rs1614309	 6	 29745884	 2.49E-10	 F_1444	 NS3	
rs2844559	 6	 31340075	 2.49E-10	 T_1646	 NS3	
rs3094013	 6	 31434366	 2.56E-10	 T_1646	 NS3	
rs1737031	 6	 29737481	 2.85E-10	 F_1444	 NS3	
rs2844531	 6	 31353171	 5.22E-10	 T_1646	 NS3	
rs3131619	 6	 31434331	 5.38E-10	 T_1646	 NS3	
rs11758516	 6	 30043486	 5.50E-10	 R_1270	 NS3	
rs2844805	 6	 29940679	 5.60E-10	 F_1444	 NS3	
rs1633028	 6	 29746367	 5.93E-10	 F_1444	 NS3	
rs3134792	 6	 31312326	 6.40E-10	 T_1646	 NS3	
rs9393989	 6	 30040084	 6.98E-10	 F_1873	 NS4B	
rs3131619	 6	 31434331	 8.43E-10	 T_1646	 NS3	
rs11758516	 6	 30043486	 8.53E-10	 R_1270	 NS3	
rs9295825	 6	 29941431	 8.97E-10	 F_1873	 NS4B	
rs1625792	 6	 31306420	 9.09E-10	 T_1646	 NS3	
rs4711207	 6	 30005754	 9.17E-10	 F_1873	 NS4B	
rs4947244	 6	 29954364	 9.17E-10	 F_1873	 NS4B	
rs9393986	 6	 29973526	 9.17E-10	 F_1873	 NS4B	
rs2844559	 6	 31340075	 9.47E-10	 T_1646	 NS3	
rs3094013	 6	 31434366	 9.82E-10	 T_1646	 NS3	
rs1610724	 6	 29761516	 1.04E-09	 F_1444	 NS3	
rs1736951	 6	 29785776	 1.07E-09	 F_1444	 NS3	
rs4711206	 6	 29987184	 1.08E-09	 F_1873	 NS4B	
rs9380150	 6	 30010492	 1.08E-09	 F_1873	 NS4B	
rs1611704	 6	 29828467	 1.12E-09	 F_1873	 NS4B	
rs9295829	 6	 30028800	 1.14E-09	 F_1873	 NS4B	
rs9357092	 6	 29984252	 1.20E-09	 F_1873	 NS4B	
rs1150735	 6	 30045199	 1.25E-09	 F_1444	 NS3	
rs3094605	 6	 31430694	 1.36E-09	 T_1646	 NS3	
rs1736946	 6	 29786732	 1.41E-09	 F_1444	 NS3	
rs2844531	 6	 31353171	 1.42E-09	 M_1646	 NS3	
rs2596565	 6	 31353329	 1.44E-09	 T_1646	 NS3	
rs1737004	 6	 29761211	 1.45E-09	 F_1444	 NS3	
rs4713274	 6	 29937493	 1.57E-09	 F_1873	 NS4B	
rs3134792	 6	 31312326	 1.70E-09	 T_1646	 NS3	
rs3094605	 6	 31430694	 1.72E-09	 T_1646	 NS3	
rs3094605	 6	 31430694	 1.98E-09	 M_1646	 NS3	
rs1611704	 6	 29828467	 2.22E-09	 L_1873	 NS4B	
rs3131619	 6	 31434331	 2.38E-09	 M_1646	 NS3	
rs2844559	 6	 31340075	 2.46E-09	 M_1646	 NS3	
rs1625792	 6	 31306420	 2.59E-09	 T_1646	 NS3	
rs3094013	 6	 31434366	 2.64E-09	 M_1646	 NS3	
rs2596565	 6	 31353329	 3.26E-09	 M_1646	 NS3	
rs2523399	 6	 29700079	 3.28E-09	 F_1444	 NS3	
rs1059449	 6	 29910698	 3.63E-09	 R_1270	 NS3	
rs76086322	 6	 29832724	 3.67E-09	 F_1873	 NS4B	
rs12193110	 6	 29937104	 3.69E-09	 F_1873	 NS4B	
rs2735054	 6	 29700615	 3.75E-09	 F_1444	 NS3	
rs11755961	 6	 29953099	 3.82E-09	 R_1270	 NS3	
rs2517930	 6	 29745075	 3.84E-09	 F_1873	 NS4B	
rs12979860	 19	 39738787	 1.98E-09	 V_2570	 NS5B		
Table	S3:	Host	and	pathogen	suggestive	associations	(P<4x10-9).		
	
	 	
HLA allele 
HCV 
amino 
acid 
position 
Viral 
protein 
Variable 
amino acids 
at this site 
Associated 
amino acid P q value 
In a 
known 
epitope? 
A*01:01 1444 NS3 FY F 9.63E-33  < 4.00E-04 Yes 
B*08:01 1646 NS3 MTAVSI T 2.89E-12  < 4.00E-04 No 
A*68:02 1344 NS3 TVA T 3.68E-10  < 4.00E-04 No 
A*02:01 1873 NS4B LFKICVPRMTA F 4.06E-10  < 4.00E-04 No 
A*31:01 1270 NS3 RKHS H 4.21E-10  < 4.00E-04 Yes 
A*68:02 1341 NS3 VA V 2.43E-09 4.44E-04 No 
A*68:02 1452 NS3 IV I 6.98E-09 4.44E-04 No 
A*32:01 2540 NS5B RSKHNQC R 7.45E-09 6.00E-04 Yes 
A*32:01 2537 NS5B NDHSYEAI N 1.13E-08 7.27E-04 Yes 
B*51:01 1380 NS3 ILV L 3.22E-08 1.67E-03 Yes 
A*31:01 2510 NS5B AKQSEMGLTV A 4.96E-08 2.14E-03 No 
B*13:02 1635 NS3 ITVLAF T 7.38E-08 3.13E-03 No 
B*38:01 2034 NS5A 
STNLPIAQV
DKEMGRF
W 
P 7.56E-08 3.13E-03 Yes 
B*15:01 1290 NS3 KPARS R 1.25E-07 4.47E-03 Yes 
B*07:02 42 C PL P 1.55E-07 5.00E-03 Yes 
A*33:03 1282 NS3 NVTSA T 1.73E-07 5.26E-03 Yes 
C*07:02 42 C PL P 2.27E-07 6.10E-03 Yes 
A*26:01 2605 NS5B EAGVK G 2.61E-07 6.64E-03 Yes 
C*07:01 1646 NS3 MTAVSI T 3.01E-07 7.39E-03 No 
C*15:02 561 E2 VTLI L 5.70E-07 1.50E-02 No 
DQA1*05:01 1646 NS3 MTAVSI T 7.24E-07 1.76E-02 No 
A*02:11 2600 NS5B QKRSAL Q 1.01E-06 3.12E-02 Yes 
B*18:01 2144 NS5A ED E 1.16E-06 3.28E-02 Yes 
A*30:02 1585 NS3 YF Y 1.19E-06 3.28E-02 No 
A*02:01 744 E2 ATVS T 2.25E-06 5.72E-02 No 
DQB1*06:01 2385 NS5A CLTIYMV Y 2.62E-06 6.03E-02 No 
B*51:01 2148 NS5A MTVSCKLIANR V 2.77E-06 6.07E-02 Yes 
B*40:06 2152 NS5A NH N 3.76E-06 7.38E-02 Yes 
B*41:02 109 C PQSAL S 4.29E-06 8.09E-02 No 
DQB1*06:01 2687 NS5B FLTYIVH Y 4.84E-06 8.59E-02 No 
DQB1*06:01 636 E2 FVIYLQ L 5.10E-06 8.68E-02 Yes 
A*33:03 330 E1 VALMITG I 5.65E-06 9.20E-02 No 
B*13:02 348 E1 IVLMAF M 5.96E-06 9.44E-02 No 
B*51:01 2713 NS5B IMLV L 6.35E-06 9.67E-02 No 
B*51:01 561 E2 VTLI L 6.68E-06 9.85E-02 No 
DQB1*06:01 235 E1 TKAIVRQENGSDMHL Q 6.87E-06 1.01E-01 No 
DRB1*03:01 1646 NS3 MTAVSI T 7.55E-06 1.03E-01 No 
C*04:03 1873 NS4B LFKICVPRMTA I 7.62E-06 1.03E-01 No 
B*07:02 48 C AT A 7.80E-06 1.03E-01 Yes 
A*25:01 2821 NS5B RKCIQL R 8.31E-06 1.04E-01 No 
B*57:01 524 E2 AVTNLDSMIREKH V 8.55E-06 1.05E-01 No 
DQB1*06:01 2355f NS5A NSDTGCAIYEV G 9.20E-06 1.05E-01 No 
C*12:03 2034 NS5A 
STNLPIAQV
DKEMGRF
W 
P 9.31E-06 1.05E-01 Yes 
A*33:03 2566 NS5B CS C 1.00E-05 1.05E-01 No 
C*12:02 1496 NS3 LPHQT P 1.05E-05 1.05E-01 No 
A*68:01 1587 NS3 TAVI T 1.06E-05 1.05E-01 No 
A*02:06 707 E2 SPA A 1.06E-05 1.05E-01 Yes 
A*33:03 2049 NS5A PS P 1.13E-05 1.06E-01 No 
A*33:03 2103 NS5A TVI V 1.13E-05 1.06E-01 No 
A*02:05 718 E2 FWLIVYCT F 1.14E-05 1.06E-01 No 
A*33:01 2813 NS5B ASTV V 1.21E-05 1.07E-01 No 
DQB1*06:01 1699 NS4A EQD Q 1.21E-05 1.07E-01 No 
DQB1*02:01 1646 NS3 MTAVSI T 1.33E-05 1.13E-01 No 
B*41:02 2221 NS5A HAYGSTF Y 1.38E-05 1.15E-01 No 
A*31:01 636 E2 FVIYLQ Y 1.43E-05 1.17E-01 Yes 
A*02:06 2355f NS5A NSDTGCAIYEV G 1.49E-05 1.19E-01 No 
DQB1*05:02 475 E2 ATDEYNVKG E 1.52E-05 1.20E-01 Yes 
A*33:03 2747 NS5B DQGCSEALNVR C 1.59E-05 1.22E-01 No 
B*41:02 2209 NS5A PLVA P 1.72E-05 1.26E-01 No 
B*41:01 2548 NS5B EAGD E 1.86E-05 1.34E-01 Yes 
C*04:03 210 E1 SGNDRKATQ G 1.88E-05 1.34E-01 No 
C*14:02 2148 NS5A MTVSCKLIANR V 1.91E-05 1.34E-01 Yes 
DRB1*12:01 1507 NS3 RK R 1.93E-05 1.34E-01 Yes 
B*35:02 2457 NS5B VI V 2.08E-05 1.48E-01 No 
DQB1*06:01 1250 NS3 NTKSDH S 2.38E-05 1.65E-01 Yes 
DQB1*06:01 1630 NS3 PAS A 2.44E-05 1.65E-01 No 
DQB1*06:01 2169 NS5A SEAFTCDHGL T 2.44E-05 1.65E-01 No 
B*49:01 1113 NS3 AS A 2.64E-05 1.69E-01 No 
A*33:03 934 NS2 FIVLCMA M 2.64E-05 1.69E-01 Yes 
DQB1*06:01 71 C SRTPNA R 2.65E-05 1.69E-01 Yes 
B*13:01 348 E1 IVLMAF V 2.69E-05 1.69E-01 No 
A*33:03 2369a NS5A VAMEDTLGQ D 2.80E-05 1.74E-01 No 
DQB1*06:01 2345 NS5A ARQKLSVT L 2.85E-05 1.74E-01 No 
A*68:01 1087 NS3 SNTAP S 2.93E-05 1.75E-01 No 
DQB1*06:01 2355e NS5A EDGTAKQP T 2.95E-05 1.75E-01 No 
A*33:03 2675 NS5B SA S 2.98E-05 1.75E-01 No 
B*13:01 454 E2 QEHDGARLSYKP D 2.99E-05 1.75E-01 Yes 
A*68:02 1177 NS3 AVT A 3.05E-05 1.75E-01 No 
B*18:01 1192 NS3 AST A 3.14E-05 1.76E-01 Yes 
B*15:01 2470 NS5B KR K 3.19E-05 1.77E-01 No 
A*33:03 2500 NS5B AG A 3.31E-05 1.81E-01 Yes 
B*57:01 1759 NS4B AVQTINGSD A 3.38E-05 1.83E-01 No 
DQB1*06:01 1019 NS2 RTKIAVQ K 3.53E-05 1.86E-01 No 
C*01:02 2088 NS5A NSDTGE D 3.53E-05 1.86E-01 No 
DQB1*06:01 2320 NS5A GSPAKDRVTNQ R 3.58E-05 1.86E-01 Yes 
A*33:03 529 E2 WFY W 3.62E-05 1.86E-01 No 
A*02:11 1875 NS4B TSNAG N 3.68E-05 1.86E-01 Yes 
C*14:02 1960 NS4B LVM L 3.69E-05 1.86E-01 No 
B*40:01 2247 NS5A EDNSKMGQ D 4.11E-05 1.96E-01 No 
B*15:18 2218 NS5A HNQ Q 4.11E-05 1.96E-01 No 
A*33:03 2033 NS5A AKSG K 4.16E-05 1.96E-01 Yes 
A*33:03 962 NS2 AQTSNEDGKV E 4.20E-05 1.96E-01 No 
A*33:03 763 P7 HNYQSR Q 4.25E-05 1.96E-01 No 
DQB1*06:02 190 C ASTVD A 4.26E-05 1.96E-01 No 
B*48:01 1378 NS3 KR K 4.26E-05 1.96E-01 Yes 
B*41:02 2799 NS5B KRNGDMHQ K 4.28E-05 1.96E-01 No 
B*07:02 47 C RCG R 4.42E-05 1.96E-01 Yes 
DQB1*06:01 2797 NS5B KRANQETSV A 4.43E-05 1.96E-01 No 
DQB1*06:01 2051 NS5A TMKLARIS L 4.48E-05 1.96E-01 No 
DQB1*06:01 2682 NS5B CVIR I 4.48E-05 1.96E-01 No 
A*33:03 872 NS2 GSA S 4.48E-05 1.96E-01 No 
DQB1*06:01 580 E2 FLIYSVKHTRMCAND K 4.51E-05 1.96E-01 No 
DQB1*06:01 2861 NS5B RQKC K 4.51E-05 1.96E-01 No 
DQB1*06:01 332 E1 MLI L 4.53E-05 1.96E-01 No 
DQB1*06:01 16 C INVTPSHLAY P 4.55E-05 1.96E-01 No 
A*33:03 2618 NS5B QAKSRG K 4.56E-05 1.96E-01 No 
A*33:03 271 E1 MLVIATF M 4.63E-05 1.96E-01 No 
DQB1*06:01 49 C TAVPS V 4.68E-05 1.96E-01 Yes 
DQA1*01:01 2486 NS5B TSNIAKVD T 4.71E-05 1.96E-01 Yes 
B*35:01 2754 NS5B ARTVQESI A 4.74E-05 1.96E-01 No 
B*49:01 1073 NS3 TSCPAIV S 4.80E-05 1.96E-01 No 
A*33:03 2466 NS5B SACTPFV A 4.81E-05 1.96E-01 No 
B*14:01 2047 NS5A ATVS V 4.82E-05 1.96E-01 No 
A*68:01 1846 NS4B RK R 4.86E-05 1.96E-01 Yes 
A*29:02 442 E2 FILV F 4.90E-05 1.96E-01 No 
C*16:01 1986 NS5A TSMILAGE T 5.04E-05 1.96E-01 No 
B*35:01 2220 NS5A PKMLVNTHSRID P 5.24E-05 1.96E-01 No 
DQA1*03:01 785 P7 LMVAI M 5.32E-05 1.96E-01 No 
B*08:01 1444 NS3 FY F 5.41E-05 1.96E-01 Yes 
A*33:03 2305 NS5A DGATN D 5.44E-05 1.96E-01 No 
A*02:05 786 P7 VAITML V 5.51E-05 1.96E-01 No 
B*08:01 2955 NS5B NKRTH K 5.51E-05 1.96E-01 Yes 
B*18:01 2995 NS5B CSGFY C 5.54E-05 1.96E-01 No 
DQB1*06:01 2809 NS5B TEIAVKD E 5.58E-05 1.96E-01 No 
DQB1*06:01 2732 NS5B DTVSIEY S 5.58E-05 1.96E-01 No 
DQB1*06:01 1140 NS3 ILV I 5.69E-05 1.96E-01 Yes 
DQB1*06:01 2374 NS5A GETRLDSPVIAK D 5.77E-05 1.96E-01 No 
B*13:01 2366 NS5A TASGINDVP A 5.84E-05 1.96E-01 No 
B*37:01 1078 NS3 MLTIVC T 5.86E-05 1.96E-01 No 
B*51:01 553 E2 TAVS A 5.91E-05 1.96E-01 No 
DQB1*06:01 2184 NS5A EAQ E 6.17E-05 1.96E-01 No 
A*02:06 2136 NS5A PTSIMARVQLK S 6.17E-05 1.96E-01 No 
DQB1*06:02 1703 NS4A QERK R 6.18E-05 1.96E-01 No 
A*33:03 2051 NS5A TMKLARIS L 6.21E-05 1.96E-01 No 
A*33:03 1266 NS3 SATMVI M 6.21E-05 1.96E-01 Yes 
A*33:03 1027 NS3 AS A 6.21E-05 1.96E-01 No 
A*33:03 1019 NS2 RTKIAVQ K 6.24E-05 1.96E-01 No 
A*33:03 2858 NS5B ITVQMSNL Q 6.24E-05 1.96E-01 No 
A*33:03 2861 NS5B RQKC K 6.24E-05 1.96E-01 No 
A*33:03 1368 NS3 GST T 6.24E-05 1.96E-01 Yes 
A*33:03 2087 NS5A AST S 6.24E-05 1.96E-01 No 
A*33:03 2184 NS5A EAQ A 6.24E-05 1.96E-01 No 
A*33:03 16 C INVTPSHLAY P 6.28E-05 1.96E-01 No 
A*33:03 1221 NS3 QEHNM E 6.31E-05 1.96E-01 No 
A*33:03 2320 NS5A GSPAKDRVTNQ R 6.31E-05 1.96E-01 Yes 
A*33:03 2430 NS5B LI L 6.31E-05 1.96E-01 No 
A*33:03 187 C HVICLQTYPNS C 6.35E-05 1.96E-01 No 
DRB1*08:03 385 E2 TAIS A 6.36E-05 1.96E-01 No 
A*33:03 2536 NS5B IVM M 6.42E-05 1.96E-01 No 
A*33:03 49 C TAVPS V 6.42E-05 1.96E-01 Yes 
DRB1*11:04 590 E2 PH P 6.43E-05 1.96E-01 No 
B*49:01 312 E1 HTARQ H 6.56E-05 1.99E-01 No 
A*11:01 574 E2 GERAKDSTVPMIHL E 6.64E-05 2.00E-01 No 
	
Table	S4.	Associations	between	HLA	alleles	and	viral	amino	acids	at	a	20%	
false	discovery	rate.	For	each	combination	of	HLA	allele	and	viral	site,	only	the	
most	significant	associated	amino	acid	at	the	site	is	reported.	The	amino	acids	in	the	“variable	amino	acids	at	this	site”	column	are	sorted	by	decreasing	frequency	such	that	the	first	shown	amino	acid	is	the	most	common	amino	acid	at	the	site.	
	
	
	
Figure	S5.	Linkage	disequilibrium	between	the	HLA	alleles.	Only	alleles	that	present	at	least	one	pairwise	r2>0.5	are	shown	here.		
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	Figure	 S6.	 Scatter	 plot	 of	 -log10(P)	 of	 association	 tests	 performed	 in	 the	
White	ancestry	patient	 infected	with	genotype	3a	virus	against	 the	whole	
cohort.	Top)	Host	HLA	alleles	and	viral	amino	acids	association	study.	Middle)	
INFL4	genotypes	(rs12979860,	CC	vs.	non-CC)	and	viral	amino	acids	association	study.	 Bottom)	 Viral	 load	 and	 viral	 amino	 acids	 association	 study.	 Our	phylogenetically	corrected	Fisher’s	exact	test	accounts	for	the	confounding	effect	of	population	structure	of	the	host	and	the	virus,	by	estimating	the	within	patient	evolution	of	the	virus.	Performing	the	tests	in	a	subset	of	the	data	where	the	host	and	 viral	 ancestry	 are	 homogenous,	 results	 in	 highly	 correlated	 P-values	 for	small	P-values.	
	
	HLA allele 
HCV 
amino acid 
position 
Viral 
protein 
Variable 
amino acids 
at this site 
Associated 
amino acid P q value 
In a 
known 
epitope? 
C*07:02 42 C PL P 1.99E-07 1.33E-03 Yes 
B*07:02 42 C PL P 8.07E-07 5.81E-03 Yes 
B*41:02 109 C PQSAL S 9.84E-06 4.93E-02 No 
B*13:02 348 E1 ILVM I 1.25E-06 8.78E-03 No 
C*08:02 372 E1 ATVIFC I 9.41E-06 4.93E-02 No 
A*29:02 444 E2 YHFRVWL Y 4.02E-06 2.39E-02 No 
DRB1*14:04 905 NS2 ATSC S 5.58E-07 4.20E-03 No 
A*31:01 1270 NS3 RKHS R 6.20E-08 3.64E-04 Yes 
B*15:01 1290 NS3 KRSA R 3.64E-06 2.39E-02 Yes 
A*68:02 1341 NS3 VA V 9.93E-07 6.91E-03 No 
A*68:02 1344 NS3 TVA T 9.22E-11 <2.50E-04 No 
B*51:01 1380 NS3 ILV L 2.10E-07 1.38E-03 Yes 
A*01:01 1444 NS3 FY F 7.18E-24 <2.50E-04 Yes 
A*68:02 1452 NS3 IV I 3.84E-07 2.89E-03 No 
B*13:02 1635 NS3 ITVL T 1.65E-07 1.00E-03 No 
B*08:01 1646 NS3 MTSAVI T 2.01E-10 <2.50E-04 No 
C*07:01 1646 NS3 MTSAVI T 1.40E-08 <2.50E-04 No 
B*57:01 1759 NS4B AVTGNSDI A 4.01E-06 2.39E-02 No 
A*02:01 1873 NS4B LFCIPRM F 2.58E-08 2.50E-04 No 
B*38:01 2034 NS5A STLPQKVAIRMFW P 6.35E-08 3.64E-04 Yes 
C*12:03 2034 NS5A STLPQKVAIRMFW P 3.99E-06 2.39E-02 Yes 
B*18:01 2144 NS5A ED E 2.36E-06 1.67E-02 Yes 
B*51:01 2148 NS5A MTVSLKIA V 4.60E-07 3.16E-03 Yes 
C*14:02 2148 NS5A MTVSLKIA V 2.32E-06 1.67E-02 Yes 
B*40:01 2248 NS5A TSKAN T 9.62E-06 4.93E-02 No 
DQA1*01:01 2486 NS5B TIANSV T 5.12E-06 2.90E-02 Yes 
A*31:01 2510 NS5B AKEQGMSVT A 1.79E-06 1.35E-02 No 
A*32:01 2537 NS5B NDYEI N 4.77E-06 2.75E-02 Yes 
A*32:01 2540 NS5B RHSNC R 5.96E-12 <2.50E-04 Yes 
B*51:01 2713 NS5B ILMV I 1.25E-08 <2.50E-04 No 
A*25:01 2821 NS5B RCQL R 2.51E-06 1.73E-02 No 
	
Table	 S5.	 Associations	 between	 HLA	 alleles	 and	 viral	 amino	 acids	 in	
patients	with	self	 reported	White	ancestry	and	 infected	with	genotype	3a	
virus	at	a	5%	false	discovery	rate.	For	each	combination	of	HLA	allele	and	viral	site,	only	the	most	significant	associated	amino	acid	is	reported.	The	first	amino	acid	 at	 “variable	 amino	 acids	 at	 this	 site”	 column	 indicates	 the	most	 common	amino	acid	at	the	site	in	the	data.	
	
	Figure	 S7.	Sequence	 logo	 representations	 of	 the	 virus	 nucleotide	 and	 the	
amino	acid	profiles	around	position	1444.	The	dots	represent	the	association	between	 the	human	variants	 (SNP	 rs3095267	 (blue),	HLA-A*01:01	 (green)	 and	amino	 acid	N77del	 in	HLA-A	protein	 (red))	 and	 the	 viral	 variants	 (nucleotides	(triangle)	 and	 amino	 acids	 (circle)).	 The	 green	 region	 indicates	 the	experimentally	validated	epitope	for	HLA-A*01	allele.	SNPs	and	HLA	amino	acids	in	the	MHC	region	were	 imputed	using	SNP2HLA	program.	While	rs3129073	is	the	 most	 associated	 genotyped	 SNP	 with	 Y1444F;	 rs3095267	 is	 the	 most	associated	imputed	SNP.					
	
	
Figure	 S8.	 Association	 analysis	 across	 the	 MHC	 region	 for	 presence	 and	
absence	 of	 F	 amino	 acid	 at	 site	 1444,	whilst	 conditioning	 (including	 as	 a	
covariate)	on	genotypes	at	rs3095267	(top	imputed	SNP)	and	HLA-A*01:01.		
	
	
Figure	 S9.	Bi-directionality	 of	 escape	 and	 reversion	 for	 viral	 amino	 acid	
sites	 associated	with	 HLA	 alleles	 at	 20%	 FDR.	Here	we	plotted	 the	 log10	of	odds	ratio	of	the	first	part	of	the	2x4	contingency	table	against	the	log10	of	odds	ratio	of	the	second	part	of	the	table	only	for	sites	that	had	sufficient	observations	to	 estimate	 the	 odds	 ratio	 of	 escape	 and	 reversion.	 An	 escape	mutation	 away	from	 the	 wild	 type	 amino	 acid	 in	 the	 people	 with	 the	matched	 HLA	 alleles	 is	usually	associated	with	fitness	cost	for	the	virus.	Therefore	it	is	expected	that	in	people	without	that	HLA	allele	 for	the	escape	mutation	to	reverse	to	wild	type.	This	 is	 the	assumption	of	bi-directionality.	There	 is	a	negative	correlation	 (R=-0.65,	P<0.01)	in	the	log10	of	odds	ratio	of	escape	and	reversion.																		
HCV 
amino 
acid 
position 
Viral 
protein 
Variable amino 
acids at this 
site 
Associated 
amino acid P q value 
In a 
known 
epitope? 
2570 NS5B AVTISGLNE V 1.94E-11 <2.86E-04 No 
2991 NS5B HYLFVMIRW H 1.17E-07 <2.86E-04 No 
60 C GEDRSA G 9.63E-07 2.86E-04 No 
2576 NS5B PAST P 2.05E-06 2.86E-04 No 
576d E2 EGDASTQNKPRVWL E 2.16E-06 2.86E-04 No 
741 E2 IVL I 2.52E-06 2.86E-04 No 
500 E2 SLARKTQPVGEI S 5.80E-06 1.11E-03 No 
2414 NS5A SNQGEKDTHR S 6.11E-06 1.20E-03 No 
501 E2 SNTDGKERQLH S 2.50E-05 6.77E-03 No 
109 C PQSLA P 5.20E-05 1.35E-02 No 
578 E2 DHLNSYTEGRFAICVPQK D 1.04E-04 2.70E-02 No 
	
Table	S6.	Host	IFNL4	SNP	association	with	HCV	amino	acids	at	FDR	of	5%.		
	
	
	
Region	
Beta		
(effect	size)	
95%	
confidence	
interval	(beta)	 P	
HVR1	 0.029	 -0.024	–	0.083	 2.82E-01	
HVR2	 0.394	 0.230	–	0.559	 2.53E-06	
PePHD	 0.155	 -0.284	–	0.593	 4.88E-01	
ISDR	 0.349	 0.157	–	0.541	 3.51E-04	
PKR-BD	 0.158	 0.034	–	0.282	 1.23E-02	
HVR3	 0.064	 -0.050	–	0.179	 2.71E-01	
	
Table	S7.	Number	of	changes	from	the	viral	population	consensus	in	IFNL4	
CC	 and	 non-CC	 individuals	 in	 regions	 of	 interest	 in	 genotype	 3a	 isolates.	Beta	column	shows	the	effect	size	on	the	number	of	changes	from	the	consensus	for	patients	with	CC	genotype	relative	to	patients	with	non-CC	genotype.	Poisson	regression	 was	 used	 with	 the	 counts	 of	 changes	 relative	 to	 consensus	 as	 the	independent	variable	and	the	IFNL4	genotypes	as	predictors.	
	
	
	
Figure	 S10.	 Association	 between	 dN/dS	 and	 IFNL4	 genotypes	 at	 the	 viral	
gene	 level.	 For	 each	 viral	 gene	 the	 rate	 of	 synonymous	 and	 non-synonymous	mutations	were	estimated	 for	all	 isolates.	The	difference	 in	 the	mean	dN/dS	 in	CC	and	non-CC	patients	is	nominally	significant	in	E1,	E2	NS3	and	NS5B	genes.	
	
		
Figure	S11.	Sliding	window	analysis	of	dN	and	dS	along	viral	genome.	Using	a	window	size	of	31	nucleotides,	moving	one	codon	at	a	time,	the	pairwise	rate	of	synonymous	and	non-synonymous	mutations	were	estimated.	The	green	regions	from	 left	 to	 right	 indicate	 HVR1,	 HVR2	 ISDR	 and	HVR3	 regions.	 The	 red	 lines	indicate	the	11	sites	associated	with	IFNL4	genotypes.	Top	panel)	Mean	rates	of	synonymous	and	non-synonymous	mutations	for	all	genotype	3a	isolates.	Middle	panel)	Mean	 dN/dS	 ratio	 for	 IFNL4	 CC	 and	 non-CC	 individuals.	 Bottom	 panel)	Difference	 in	 mean	 of	 the	 dN/dS	 for	 IFNL4	 CC	 and	 non-CC	 individuals.	 The	difference	in	mean	is	higher	in	CC	individuals	above	0	(log10(P)	is	plotted)	and	is	higher	in	non-CC	individuals	below	0	(-log10(P)	is	plotted).	
	
	
Figure	 S12.	 Interaction	 between	 IFNL4	 genotypes	 and	 HLA	 allele	 escape	
mutations.	For	the	sites	associated	with	HLA	alleles	at	a	20%	FDR,	we	tested	for	interaction	between	IFNL4	genotypes	and	HLA	allele	using	a	logistic	regression.	Each	dot	is	the	-log10(P)	for	the	interaction	term	between	INFL4	genotypes	and	the	HLA	allele	associated	with	the	amino	acids	at	the	site.	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
Figure	S13.	Genotype	3a	Replicon	assay	for	a	subset	of	sites	associated	with	
IFNL4	 and	 nominally	 associated	 with	 viral	 load.	 Top	 panel,	 two	 sites	associated	with	IFNL4	genotypes.		Middle	panel,	eight	sites	nominally	associated	with	 viral	 load.	Bottom	panel,	 replicon	 assay	 for	 site	 2414	which	 is	 associated	both	 with	 IFNL4	 genotypes	 and	 viral	 load.	 A	 change	 from	 a	 serine	 (S)	 to	 an	asparagine	(N)	resulted	 in	a	10-fold	 increase	 in	viral	replication.	GND	indicates	negative	 control.	 Y-axis	 is	 the	 luciferase	 assay	 in	 normalized	 raw	 light	 units	(RLU).	
	
	
Figure	 S14.	 Viral	 amino	 acids	 affect	 on	 viral	 load	 vs.	 IFNL4	 odds	 ratio	 of	
escape	from	consensus	for	viral	sites	associated	with	IFNL4	genotypes	at	a	
20%	FDR.	We	only	plotted	sites	that	had	at	least	10	non-consensus	amino	acids	in	each	of	IFNL4	CC	and	non-CC	genotypes.	On	x-axis	we	have	plotted	the	log10	of	odds	ratio	for	the	contingency	table	where	rows	are	the	counts	of	CC	and	non-CC	patients	 and	 the	 columns	 are	 the	 counts	 for	 the	 change	 and	 no	 change	 on	 the	terminal	branches	of	the	tree	from	the	most	common	amino	acid	(log10(OR)	>	0	is	interpreted	as	proportion	of	changes	from	“most	common	amino	acid”	to	“any	other	amino	acid”	 is	higher	 in	CC	patients	 than	non-CC	patients).	On	y-axis	 the	effect	size	of	non-consensus	amino	acids	 (relative	 to	consensus	amino	acid)	on	viral	load	is	plotted	(estimated	using	linear	regression	where	in	the	top	panel	the	
IFNL4	genotypes	are	added	as	a	covariate).	In	the	bottom	two	panels,	the	effect	size	of	the	non-consensus	amino	acid	on	viral	load	was	estimated	only	in	IFNL4	CC	 and	 non-CC	 patients.	 The	 red	 dot	 represents	 the	 viral	 position	 2414,	associated	with	IFNL4	genotypes	and	viral	load.	
		
		
Figure	 S15.	 Viral	 amino	 acids	 affect	 on	 viral	 load	 vs.	 IFNL4	 odds	 ratio	 of	
escape	from	consensus	 for	viral	sites	associated	with	 IFNL4	genotypes	 for	
all	sites.	We	only	plotted	sites	that	had	at	least	10	non-consensus	amino	acids	in	each	of	IFNL4	CC	and	non-CC	genotypes.	On	x-axis	we	have	plotted	the	 log10	of	odds	ratio	for	the	contingency	table	where	rows	are	the	counts	of	CC	and	non-CC	patients	 and	 the	 columns	 are	 the	 counts	 for	 the	 change	 and	 no	 change	 on	 the	terminal	branches	of	the	tree	from	the	most	common	amino	acid	(log10(OR)	>	0	is	interpreted	as	proportion	of	changes	from	“most	common	amino	acid”	to	“any	other	amino	acid”	 is	higher	 in	CC	patients	 than	non-CC	patients).	On	y-axis	 the	
effect	size	of	non-consensus	amino	acids	 (relative	 to	consensus	amino	acid)	on	viral	load	is	plotted	(estimated	using	linear	regression	where	in	the	top	panel	the	
IFNL4	genotypes	are	added	as	a	covariate).	In	the	bottom	two	panels,	the	effect	size	of	the	non-consensus	amino	acid	on	viral	load	was	estimated	only	in	IFNL4	CC	 and	 non-CC	 patients.	 The	 red	 dot	 represents	 the	 viral	 position	 2414,	associated	with	IFNL4	genotypes	and	viral	load.	
	
	
							
